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ABSTRACT 
Andrew G. Brandmaier 
 
TRP-1 AS A MODEL TUMOR ANTIGEN FOR IMMUNOTHERAPY AND  
IMMUNE TOLERANCE IN THE THYMUS 
 
Tolerance mechanisms, which collectively work to prevent autoimmunity, play a 
key role in suppressing the adaptive immune response to tumor antigens.  This 
phenomenon is attributed to the extensive overlap of tumor associated antigens 
with self peptides.  We studied immune tolerance to tumor antigen TRP-1, a 
melanoma associated glycoprotein.  Vaccination of Wild type (WT) and TRP-1 
deficient (Bw) mice with TRP-1 antigen highlighted the substantial effect of 
tolerance on the T cell response: in the Bw population a log-fold differential was 
observed with greater clonal numbers and higher intensity of cytokine release 
from the antigen specific CD4+ T cell population.  Additionally, TRP-1-reactive T 
cells derived from Bw mice demonstrated significantly more efficacious tumor 
treatment ability than WT donor cells when adoptively transferred into recipients 
challenged with B16 melanoma.  Furthermore, donor Bw T cells were so potent 
as to overcome suppression by endogenous Tregs in mediating their effect.  
Probing for a tolerance mechanism, we isolated medullary thymic epithelial cells 
(mTECs) from WT mice and found that they promiscuously express TRP-1.  
Unexpectedly, TRP-1 expression in mTECs was found to occur independently of 
the prominent Autoimmune Regulator (Aire) transcription factor as well as the 
melanocyte specific transcription factor, mMitf.  Our most recent data suggests 
that thymic dendritic cells may also express copies of the TRP-1 transcript.  
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Future transplant studies will test whether mTECs or thymic dendritic cells 
directly tolerize TRP-1 specific T cells.  Overall, these findings highlight the 
relevance of central tolerance to cancer immunology and compel further 
investigation of its mechanistic impact on the development of tumor-reactive T 
cells. 
 
 
                                                                   Christopher E. Touloukian, M.D., Chair 
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ABBREVIATIONS 
 
Ab  Antibody 
 
ABS  Applied Biosystems 
 
Aire  Autoimmune Regulator 
 
APC  Antigen Presenting Cell 
 
BL/6  Mice on the C57BL/6 background 
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MDA  Melanocyte Differentiation Antigen 
 
MHC  Major Histocompatibility Complex 
 
Mitf  Micropthalmia-associated transcription factor 
 
mRNA Messenger RNA  
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NK  Natural Killer 
 
Nm  Nanomolar 
 
qRT-PCR Quantitative Real-time polymerase chain reaction 
 
RAG  Recombinase activator gene 
 
RBC  Red blood cell 
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TCR  T cell receptor 
 
Teff  T effector cell 
 
Tg  Transgenic  
 
Th (#)  T helper cell (classification number) 
 
Treg  T regulatory cell 
 
TRP-1  Tyrosinase related protein 
 
Tyrp1  Tyrosinase related protein 1, gene symbol 
 
Tyrp1bw C57BL/6 mice of the Tyrp1bw/bw genotype 
 
WT  C57BL/6 mice of the Tyrp1+/bw genotype 
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INTRODUCTION 
T cells 
T cells play a central role in generating and modulating adaptive immune 
responses against peptide antigens.  Classic αβ T cells have a range of 
functional profiles that are categorized by phenotype, but they share a common 
paradigm in that each expresses a unique surface molecule, the T cell receptor 
(TCR), which is a dimer of two globulin proteins, α and β.  Individual TCRs are 
able to recognize specific antigenic peptides, known as epitopes, enabling 
immune detection of potentially dangerous challengers to the host such as 
microbes or tumor cells.  The TCR variable region, a composite of the α and β 
chains, is the antigen binding end of the molecule.  Each unique α and β chain is 
produced in a recombination step that entails random rearrangements of specific 
regions of the TCR gene (V + J for α and V + D + J for β) facilitated by the 
recombination activating proteins (Rag-1 and Rag-2).  This process creates a 
diverse repertoire of TCRs which facilitates recognition of a massive spectrum of 
antigenic epitopes by the T cell population (1).  
 
T cell recognition of an epitope occurs when its TCR binds with affinity to an 
antigenic peptide displayed by a molecular complex on an adjacent cell, the 
antigen presenting cell (APC).  These display molecules are gene products of the 
major histocompatibility complex (MHC).  Biochemically, they are globulin 
proteins that serve as vehicles for APCs to present peptide fragments on their 
surface, and the composite MHC:peptide molecules comprise one end of an 
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immunological synapse (2).  Individual TCRs have uniquely arranged variable 
regions which allows them to recognize a specific cognate MHC:peptide 
complex; higher affinity binding generally leads to more potent stimulation.  
Studies have shown that synthetically tweaking natural peptide epitopes with 
truncations or minor amino acid substitutions to optimize affinity for a particular 
TCR can enhance this interaction (3).  In general, individual T cells within the 
host repertoire are very precise in responding to a corresponding MHC:peptide 
complex.  When recognition occurs and TCRs bind the complex with affinity, an 
immunological synapse is formed. 
 
Formation of the immunological synapse is the key process that singles the T cell 
clone to mount an immune response.  The αβ surface receptor transmits signals 
to other molecules associated with the TCR at the surface of the cell membrane, 
including the TCR zeta chain.  Zeta contains immunoreceptor tyrosine-based 
activation motif domains (ITAMs) that are phosphorylated by the Src family 
kinase, Lck, when TCR binding occurs.  The tyrosine kinase Zap70 is recruited to 
this domain and activated (4).  Zap70 targets LAT (linker of T cell activation) for 
tyrosine phosphorylation, and LAT subsequently recruits an array of signaling 
molecules that mediate downstream signaling cascades leading to calcium 
release, Ras activation, actin polymerization and modulation of transcription 
(5,6).  Ultimately, if this stimulation occurs in an inflammatory context with 
activation of costimulatory cell surface molecules, particularly the B7 family, the T 
cell will become activated (7).  Depending on the cell‟s phenotype, it may 
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produce cytotoxic molecules or cytokines that coordinate an immune response to 
destroy the invading antigen.  Moreover, the antigen-specific T cell clones will 
proliferate to magnify the number of cells responding to the invading antigen.  
 
αβ T cells are classified based on phenotypic properties including their function 
and cytokine release profile.  The two overarching phenotypes are divided 
according to whether they express the CD8 or CD4 surface marker and deemed 
CD8+ or CD4+, respectively.  They are imprinted with this lineage during early 
development in the thymus (8).  In host immunity, they perform diverse but 
complementary functions to maintain protection against a spectrum of antigenic 
challenges. 
 
CD8+ T cells 
 CD8+ T cells respond to peptide epitopes presented by MHC class I complexes.  
These complexes consist of a three subunit alpha chain associated with the 
molecule  β2 microglobulin (9).  The pool of available class I antigens originates 
primarily originates from intracellular proteins that gain access to the cytosol 
where they are processed by the class I presentation pathway (10).  MHC class 
I:peptide complexes are presented on the surface of cells of nearly every tissue 
type which facilitates global immune detection of the “danger” epitopes.  This 
paradigm allows CD8+ T cells to recognize and destroy infected cells throughout 
the body in a four phase process.  First, the antigen specific T cells are activated 
by recognition of an MHC:peptide complex in conjunction with costimulation.  
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Next, the activated cell populations expand as much as 4 log fold over a period of 
5-8 days.  In the third phase, these populations contract by up to 95% over 
approximately a 1 week period.  Finally, a subset of the remaining cells 
differentiates into a memory population that can re-expand vigorously on repeat 
exposure to the offending antigen (11).  CD8+ T cells directly mediate destruction 
of antigen carrying cells by secreting molecules such as granzyme and perforin 
that cause cytolysis (12).  They also can promote target cell death by 
upregulating expression of CD95L which engages CD95 on adjacent cells and 
initiates an apoptotic signaling cascade (13).  Additionally, they may release 
cytokines such IFN-γ and TNF-α to activate other effector immune cells including 
macrophages and neutrophils (14).  Through these mechanisms, CD8+ T cells 
are able to mediate elimination of virally infected cells and tumor cells. 
 
CD4+ T cells 
CD4+ T cells recognize MHC class II:peptide complexes which encompass a 
membrane-spanning heterodimer consisting of an alpha and beta chain, each 
with two subunits.  most often presented by professional antigen presenting cells 
(APCs); the most prominent ones are dendritic cells and B cells, which can 
endocytose and process exogenous antigens for presentation.  The class II 
epitopes include both extracellular and internally produced peptides that make it 
into the appropriate endosomal pathway.  CD4+ T cells are commonly referred to 
as Thelpers for their role in releasing cytokines and chemokines that orchestrate 
other cells in the immune response, and they can adopt and sometimes 
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interchange between different subset phenotypes.  The most prominent 
examples include IFN-γ secreted by Th1 cells to promote cellular immunity, IL-4 
from Th2 cells which stimulates humoral immunity, and IL-17 from Th17 cells 
which mediates pro-inflammatory responses.  Depending on the context of their 
initial activation, CD4+ T cells can differentiate along the different helper class 
lineages with the aforementioned cytokine profiles which allows a dynamic range 
of immune responses (15,16).  Overall, CD4+ T cells are a potent and critical 
component of the host‟s adaptive immune response to foreign antigens.   
 
Tumor immunity 
The phenomenon of tumor immunity has been observed for nearly a century with 
clinical case reports documenting resolution of tumor masses following 
associated infection or inflammation proximal to a malignancy.  More specific 
confirmation of its existence was illustrated when tumor infiltrating lymphocytes 
(TIL) were identified in histological sections of malignant tissue.  Further 
investigation of TIL has revealed that T cells are one of the central immune 
agents that recognize tumor antigens; they invade malignant sites and mediate 
the anti-tumor response.  The first correlation between TIL and host survival was 
observed in melanoma patients where it was found that patients whose tumors 
had high levels of CD8+ T cell infiltration enjoyed a more favorable prognosis 
(17,18).  Since the discovery of a T cell response to tumors, investigators have 
attempted to utilize the immunogenicity of tumor-associated antigens for 
therapeutic purposes.   
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CD8+ T cells specific for melanoma-associated antigens have been the primary 
focus of cell-based melanoma immunotherapy.  Investigators have identified an 
extensive array of class I-restricted epitopes from melanoma antigens and also 
observed the significance of their cytotoxicity towards melanoma cells.  For 
example, CD8+ T cells specific for the melanoma antigen, MART-1, have been 
identified in infiltrates of the skin and retinal pigment epithelium of patients with 
autoimmune vitiligo - a cytotoxic immune response to melanocytes (19).  Several 
studies have targeted MART-1 for melanoma immunotherapy including a recent 
gene therapy study that re-engineered T cells with a Mart-1 receptor and 
achieved tumor recognition and destruction (20).  Another melanoma antigen, 
gp100, has been well characterized by Restifo and colleagues.  They showed 
that immunization of C57BL/6 mice with a recombinant vaccinia virus expressing 
the gp100 gene elicited a cytotoxic response; in vitro co-cultures of the resulting 
T cells with various melanoma cell lines stimulated potent IFN-γ cytokine release.  
Also, adoptive transfer of an expanded gp100-specific CD8+ T cell clone, derived 
from the vaccinated subjects, into mice challenged with B16 melanoma 
demonstrated superior tumor protection compared to a control group (21).  The 
MART-1 and gp100 models are two prominent examples that have illustrated the 
potency of CD8+ T cells bearing receptors specific for melanoma antigens. 
 
CD4+ T cells in tumor immunity 
Despite the apparent potency of CD8+ cytotoxic cells, increasing evidence points 
toward a central role for CD4+ T cells in sustaining the type of comprehensive 
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immune response that may be needed for successful tumor immunotherapy.  
Various studies in mice have determined that Thelper cells are essential for 
development and maintenance of CD8+ memory T cells (22).  More specifically, 
investigators have demonstrated that CD4+ T cell help is required for optimal 
induction of cytotoxic T cells against class II-negative tumors (23).  Additional 
studies have shown that CD4+ T cells exert their effects through the induction 
and maintenance of B cells and CD8+ T cells, and they are indispensable for the 
long-term maintenance of antigen-activated memory CD8+ T cells (24,25).  
Several lines of evidence also suggest that CD4+ T cells have other direct and 
indirect effects on tumor cells, including those deficient in major histocompatibility 
complex (MHC) class II, through the induction of a delayed type hypersensitivity-
like reaction.  This entails attracting inflammatory cells (macrophages, 
granulocytes, eosinophils, and natural killer (NK) cells) to the tumor 
microenvironment (26,27).  The production of IFN-γ by the activated CD4+ T cells 
has also been shown to have multiple effects, including direct tumor cytotoxicity, 
the up-regulation of MHC molecules which increases immune recognition, the 
enhancement of antigen processing, and the inhibition of tumor-induced 
angiogenesis (28-30).   
 
One of the main mechanisms postulated to connect the CD4+ and CD8+ T cell 
responses in anti-tumor immunity is antigen cross-presentation.  Dendritic cells 
endocytose, process, and present class II-restricted antigens to CD4+ T cells, 
which respond by stimulating the DCs to increase surface expression of the co-
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stimulatory molecules B7.1, B7.2, and OX-40 (31,32).  The DCs then cross-
present class I-restricted tumor epitopes to CD8+ T cells and prime them by 
ligand binding of the co-stimulatory molecules so that the T cells are optimally 
activated to mount a potent and durable response to their target (33). 
 
Tumor immunotherapy 
Tumor immunotherapy involves clinical methods that are utilized to stimulate an 
immune response with associated tumor destruction.  T cell immunotherapy, in 
particular, could entail vaccination with tumor antigens or adoptive transfer of 
reactive T cells specific for a tumor epitope to elicit a therapeutic anti-tumor 
response.  Despite several clinical studies attempting T cell immunotherapy, 
there has yet to be shown a dependable, efficacious method of eliciting 
therapeutic immune responses to known tumor antigens. To date, several 
different modalities have been employed to target melanoma, but none have 
been overly successful.  In addition to the previous examples, other attempts 
have included vaccination of patients with various melanoma differentiation 
antigens by injecting dendritic cells loaded with tumor lysates, which showed no 
appreciable efficacy (34).  In a T cell adoptive transfer trial, patients were treated 
with their own tumor infiltrating lymphocytes, after expanding them in vitro (35).  
In a more sophisticated study, a group of 15 patients with advanced stage 
melanoma received gene therapy, whereby their PBMCs were transduced with a 
retrovirus containing the gene of a MART-1 specific, class I-restricted, TCR.  
Despite the potency of the MART-1 TCR, re-infusion of these transduced PBMCs 
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achieved long-term engraftment and clinical regression in only two of the patients 
(36).  The multitude of unsuccessful attempts at immunotherapy has elicited 
interest in understanding the mechanistic barriers to its success.  A central 
hypothesis in the field of cancer immunotherapy is that immune tolerance 
prevents or suppresses T cell responses to tumor antigens because these 
antigens are present in normal self tissue (37).  The tolerance hypothesis is 
considered one of the main reasons for the shortcomings in melanoma treatment 
to date.   
 
TRP-1 and the melanosome 
Many of the target antigens for melanoma immunotherapy derive from protein 
substrates of melanocytes, the melanin producing cells present in skin and retinal 
pigment epithelium.  Melanin pigments protect the skin and eyes by absorbing 
ultraviolet radiation (38).  If they become malignant, melanocytes can develop 
into cancerous tissue (melanoma).  Immunotherapy efforts directed at melanoma 
have been advanced by the identification of antigenic proteins, melanocyte 
differentiation antigens (MDAs); these are often structural or enzymatic 
molecules contained in the melanosome, the pigment-producing organelle of 
melanocytes (Figure 1). Studies have characterized the expression and 
MHC:peptide presentation of epitopes from several MDAs including MART-1, 
gp100 and tyrosinase (39,40).  This project focused on the melanoma antigen 
TRP-1 (tyrosinase-related protein 1), which is a 75kDa molecule involved in 
melanin biosynthesis and the most abundant glycoprotein present in  
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Figure 1.  Diagram of the melanocyte. In melanocytes the characteristic 
organelle is the melanosome, a compartment that contains most of the 
melanocyte differentiation antigens.  MDAs are often enzymes and structural 
proteins that support the synthesis of melanin, the protective pigment of skin, 
hair and retinal pigment epithelium. 
Melanocyte 
Nucleus 
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melanocytes (41).  Previous work has shown that when cohorts of C57BL/6 mice 
were immunized with a vaccinia virus construct expressing one of a panel of 
melanoma antigens (gp100, MART-1, tyrosinase, TRP-1, TRP-2), TRP-1 
uniquely elicited autoimmune vitiligo.  Additionally, T cells from the TRP-1 
vaccinated mice were found to recognize and respond to a panel of melanoma 
cell lines and also provide protection against B16 melanoma in an MHC class-II 
dependent manner (42).  Because of its antigenic potency and ability to stimulate 
a CD4+ T cell response, we selected TRP-1 as an immunotherapy target. 
  
Mitf and TRP-1 transcription 
The micropthalmia transcription factor (Mitf) is an important upstream regulator of 
the program of pigment gene expression in melanocytes and melanomas.  
Several Mitf isoforms have been identified, all of which encode a basic/helix-loop-
helix/leucine zipper molecule which transactivates expression by binding to a 
conserved promoter motif called the “E-box” (43).  The M isoform (M-Mitf) is 
specific to neural crest derived melanocytes and is critical for activating 
expression of pigment proteins, melanocyte survival, and melanoma and 
melanocyte proliferation (Figure 2) (44).  A conserved promoter element, the “M-
box”, is an 11 base pair sequence shared by the tyrosinase and Tyrp1 gene 
promoters which Mitf binds to activate their transcription (45).  Clinically, Mitf 
mutations such as Waardenburg syndrome type 2 and albinism-deafness 
illustrate the gene‟s function (46-48).  Waardenburg patients can manifest  
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Figure 2.  Elements of the TRP-1 gene.  Transcription factors associating with 
the upstream promoter and enhancer elements individually upregulate TRP-1 
expression.  mMitf is the central controller of TRP-1, binding to a confined 
promoter region known as the “M box” which can individually induce TRP-1 
expression. 
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different pigment-related defects including a white forelock and patches of white 
skin.  Various mouse models of Mitf gene knockouts or mutants show ear, eye 
and coat color defects.  All of these findings highlight the significance of Mitf as a 
gene regulator in melanocytes.   
 
Thymocyte development  
To understand the T cell response in tumor immunity, it is important to consider 
early T cell development.  The process begins in the bone marrow where 
hematopoietic stem cells reside and differentiate along various progenitor 
lineages including those that populate the thymus (49,50).  Cells of the T 
progenitor lineage migrate from the bone marrow along a chemokine gradient – 
utilizing CCR7 and CCR9 – to reach the thymus (51,52).  Upon arrival, T cell 
precursors (thymocytes) are in the pro-T cell stage and do not yet express any of 
the TCR genes or associated CD3 and zeta chains.  They also lack expression of 
the CD4 and CD8 co-receptors and are thus classified as double negative (DN).  
The DN cells pass through a series of stages denoted DN1 through DN4, moving 
closer toward TCR development. 
 
The DN3 stage is the first important step for mature TCR production.  
Recombination activating genes (Rag-1 and Rag-2) are expressed, and they 
mediate the rearrangement of V, D and J regions within the TCR β gene to 
produce a TCR with a random variable region, which corresponds to the antigen-
detecting end.  On a population scale, this gene rearrangement is responsible for 
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producing the substantial diversity within the TCR repertoire (53).  Ultimately, 
each individual thymocyte expresses a uniquely rearranged TCR-β chain gene 
that, if viable, will associate with an invariant pre-α T chain and the CD3 signaling 
complex.  Aggregation of a viable β chain in this pre-TCR complex autonomously 
signals the thymocyte in a ligand-independent manner (54).  Resultant activation 
of downstream signaling cascades induces thymocyte proliferation and surface 
expression of CD4 and CD8 co-receptors which renders the thymocytes “double-
positive” (DP) (55-57).  Having already produced a functional globulin chain, the 
respective TCR-β gene of the thymocyte ceases to undergo further 
rearrangements.  Subsequent steps then produce an α chain via recombination 
of V and J regions of the gene.  During these early maturation steps, a large 
percentage of thymocytes undergo apoptosis after failing to produce a fully 
assembled αβ TCR.  Cells that survive to the DP stage must undergo 
subsequent selection processes mediated by epithelial cells of the cortex and 
medulla.  These steps, referred to as “thymic education”, include positive and 
negative selection which are the mechanisms of central tolerance that ultimately 
sculpt a functional and safe T cell repertoire for the host.  
 
Positive selection  
Following synthesis of a viable αβ TCR, DP thymocytes scan their surrounding 
environment in the thymic cortex for ligand interactions.  The histology of this 
region has been well described; it primarily consists of cortical thymic epithelial 
cells (cTECs) interspersed with fibroblasts.  Studies have defined a characteristic 
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ensemble of surface markers for cTECs - CD45- EPCAM+ Ly51+ MHC class II+ - 
a set of parameters that can be applied for cell sorting (58).  cTECs present MHC 
class I and II peptide complexes as a means to engage thymocytes and 
participate in the first phase of thymic education.  The thymocytes meander 
throughout the cortical microenvironment receiving feedback in the form of TCR 
engagement by MHC complexes on APCs.  This step, known as “positive 
selection”, promotes survival of DP cells bearing functional TCRs.  Confocal 
microscopy has illustrated the mobility of precursor thymocytes in real time, a 
pattern that has been described as “random walk migration” (52,59).  Overall, 
positive selection enriches the thymocyte population with cells that possess 
TCRs capable of adhering to host MHC molecules with at least moderate affinity.  
Thymocytes that positively interact with cTECs survive with some even bearing 
receptors that are cross-reactive for peptide and MHC (60).  Thymocytes that 
produce a TCR incapable of associating with MHC molecules on neighboring 
cTECs eventually undergo apoptosis due to lack of positive signaling.  These 
clones, which manifestly lack functional utility in that they cannot respond to the 
host APCs, are eliminated from the repertoire.  Ultimately, the positively selected 
thymocytes undergo a lineage commitment to either CD4+ SP (when selected by 
MHC class II) or CD8+ SP (when selected by MHC class I) based on differential 
intracellular signaling pathways via the tyrosine kinase and Lck molecules 
(61,62).  Having passed this stage of thymic education, the SP thymocytes 
migrate to the thymic medulla under the guidance of CCR7 for the final stage of 
central tolerance (63). 
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Negative selection and thymocyte elimination 
The thymic medulla is a unique tissue microenvironment that serves as a 
gatekeeper for SP thymocytes before they are released into the peripheral 
circulation.  It primarily consists of stromal fibroblasts, dendritic cells and 
medullary thymic epithelial cells (mTECs).  mTECs can be identified by the 
following surface marker expression profile: CD45- EPCAM+ Ly51- MHC class II+ 
(58).  Having already undergone positive selection in the cortex, the SP 
thymocyte population migrating into the medulla has a self MHC-restricted T cell 
repertoire with wide-ranging antigen recognition ability.  While this diversity of 
receptors offers broad protection against “danger” epitopes from invading 
pathogens, it also poses a potential hazard to the host from T cells that recognize 
peripheral self antigens.   
 
Autoimmunity is the generation of inflammatory responses directed against host 
epitopes, and it can occur when self-reactive thymocytes are not adequately 
removed from the T cell repertoire.  Thymic deletion is the core step of central 
tolerance whereby medullary thymic epithelial cells mediate apoptosis of 
thymocytes with TCRs specific for MHC:peptide complexes presented by the 
mTECs.  Marrack and colleagues showed selective deletion of murine 
thymocytes expressing Vβ17a, which react strongly with the I-E protein, in mice 
expressing I-E (64).  Additional studies have further characterized negative 
selection as a high-avidity process, in contrast to the lower baseline avidity 
required for positive selection.  For example, fetal thymic organ cultures from 
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mice expressing a transgenic T cell receptor showed increased thymocyte 
deletion with addition of higher concentrations of the corresponding peptide 
epitope to the culture (65).  Negative selection appears to require relatively 
extensive engagement of thymocyte TCRs with peptide:MHC complexes. 
 
Promiscuous gene expression by mTECs 
mTECs promiscuously express a spectrum of proteins from the host genome 
which creates a broad, representative pool of tissue-specific antigens, disease-
associated autoantigens and cancer-germline genes available in the thymic 
environment (66).  Epitopes from these antigens are then presented to 
developing thymocytes which mediates elimination of self-reactive cells (Figure 
3).  Bevan and colleagues have shown that mTECs directly present these self 
antigens to CD8+ thymocytes whereas DCs appear to play the major role in 
engagement and elimination of self-reactive CD4+ cells (67).  Mitotic studies of 
mTECs have characterized them as a rapidly cyclic population, with apoptosis of 
the mature subset creating a veritable reservoir of self-antigens available to DCs 
for acquisition and presentation (68).  This data is consistent with other reports 
that thymic DCs, particularly those with an activated phenotype, are constitutively 
provided with and present cytosolic as well as membrane-bound mTEC-derived 
peptides (69).   Peripheral antigens can also be transported to the thymus.  One 
study employing intravenous injection of peptide antigen into mice demonstrated 
that DCs acquire the peptide en route to the thymus where they mediate deletion  
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Figure 3.  mTEC mediated central tolerance. Diagram illustrates the current 
paradigm of the medullary thymic epithelial cell in central tolerance.  mTECs 
promiscuously express a representative ensemble of host antigens which are 
processed and presented in the form of MHC class I or II peptide complexes to 
developing thymocytes.  Cells whose TCRs bind above an, as yet, undefined 
affinity threshold are induced to undergo apoptosis.  Additionally, CD4+ T cells 
whose receptors associate with a lesser affinity undergo conversion to the 
regulatory phenotype.  Dendritic cells also have been shown to mediate central 
tolerance, particularly with thymocytes expressing class II-restricted TCRs.  DCs 
are thought to either acquire host antigen from local mTECs or transport 
endocytosed antigens from the periphery. 
Developing T cells interact with mTECs as 
part of central tolerance
mTEC
MHC Class I or II
TCR
Class IITCR
Treg conversion
Apoptosis
Apoptosis
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of corresponding SP thymocytes specific for that peptide (70).  Overall, the 
evidence shows there are several channels by which host antigens in the thymus 
are incorporated with the negative selection process. 
  
Several studies have explored the patterns of mTEC gene expression and the 
transcriptional controls for this process.  One of the first experiments 
characterized the ectopic antigen expression pattern by utilizing RT-PCR of 
mTEC RNA which detected transcripts representing a broad array of host tissue 
proteins.  These included the melanoma associated antigens, gp100 and 
tyrosinase (71).  More recent studies have attempted to determine the upstream 
transcription factors orchestrating the unique promiscuity of gene expression in 
mTECs.  Aire, the autoimmune regulator gene, has been implicated as a critical 
transcription factor responsible for this phenomenon (72).  Mathis and colleagues 
have linked defects in the Aire gene to autoimmune sequelae such as the 
APECED disease (autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy) (73).  This was clearly demonstrated in their mouse model in which 
nude mice were transplanted with WT or Aire-/- thymuses.  Only mice receiving a 
knockout thymus showed subsequent, spontaneous infiltration of immune cells 
and associated inflammatory pathology of several host tissues – salivary, 
stomach, liver, reproductive and retina (74).  A separate study on the Aire 
knockout model reported absence of Mucin 6 expression in Aire-/- mTECs 
(normally expressed in WT) with a consequent, spontaneous autoimmune 
gastritis (75).  Experiments investigating the transcriptional function of Aire have 
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actually shown that its role may be more complicated than simply promoter 
binding and transcriptional activation.  It has more recently been found to have 
histone binding sites and demonstrable interactions with nucleosomes in addition 
to its DNA binding SAND domain (76).  Furthermore, Aire is not the sole 
regulatory protein responsible for ectopic production of tissue antigens.  Some 
mTEC gene expression levels are unchanged or even increased in the absence 
of Aire (77).   Additionally, no mechanistic explanation has been elucidated for 
the various classes of tumor antigens expressed by mTECs.  This includes 
transcripts of the aforementioned melanoma antigens described by Kyewski and 
more recent purified protein studies which revealed that MUC1 and CEA are 
expressed (78).  Though additional pieces of the mTEC transcriptome continue 
to be revealed, the connection between the ectopic antigens and the factors 
regulating their expression remains relatively undefined. 
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RESEARCH OUTLINE 
We sought to determine the effect of host antigen deficiency on self-tolerance to 
tumor antigens by examining the TRP-1 antigen model.  A previously discovered 
human class II DR4 restricted peptide epitope of TRP-1, 277-297, served as the 
target for our initial experiments (79).  To model host antigen deficiency, we 
utilized Tyrp1 mutant mice, Bw, which were previously characterized by Oak 
Ridge National Laboratory as offspring from founders that had been exposed to 
gamma irradiation.  The mice were noted to exhibit a cappuccino coat color 
phenotype which has been attributed to a recessive Tyrp1 gene defect 
characterized as an inversion of exon 1 (80).  First, we attempted to examine in 
greater detail the antigen levels in the two mice.  We determined that the paucity 
of TRP-1 transcript and protein in Bw melanocyte samples as well as the 
corresponding light brown coat color validated the Bw mouse as a credible 
antigen-deficient population relative to the WT background.  WT and Bw mice 
were vaccinated with TRP-1, and their resulting T cell responses were compared 
on several parameters including numbers, cytokine potency and tumor treatment 
efficacy.  These data provided a set of metrics for gauging the impact of 
tolerance on the TRP-1 antigen in the WT background. 
 
The results from the vaccination and tumor treatment studies revealed a 
substantial difference in T cell phenotypes from the antigen-deficient Bw 
population in comparison to the WT cohort.  Collectively, they highlighted the 
major impact of tolerance on the host‟s responding T cell repertoire.  To 
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determine the source of these differences, we analyzed the potential effect of 
central tolerance, a major checkpoint of early T cell development in the thymus.  
These studies led to analyses of medullary thymic epithelial cells, which play a 
central role in deleting T cells specific for self antigens.  Importantly, we found 
that mTECs promiscuously expression TRP-1 transcript and protein.  
Furthermore, we analyzed potential transcriptional controls for this phenomenon 
and found that neither Aire nor Mitf were necessary for activation of the TRP-1 
gene.  Most recently, we have observed detectable levels of TRP-1 transcript 
expressed in dendritic cells of WT mice.  Additionally, ongoing studies are 
utilizing transgenic T cell receptor bone marrow – encoding an I-Ab restricted 
TCR reactive against murine TRP-1113-127 – for transplant experiments to probe 
deletion of TRP-1-specific thymocytes.  These experiments are aimed at 
elucidating mTEC and/or DC contribution to deletion of the TRP-1 specific 
thymocytes. 
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MATERIALS AND METHODS 
Experimental mice.  Tyrp1bw/bw mice, previously described (80), were fully 
backcrossed to C57BL/6 mice for 6 generations (81) and found to accept 
syngeneic tumor implants and skin grafts from C57BL/6 mice (data not shown). 
Murine class II-deficient, DR4-IE transgenic mice (DR4 Tg), (82) fully 
backcrossed onto C57BL/6, were purchased from Taconic Farms. To create a 
double-mutant strain expressing the Tyrp1bw mutation and the DR4-IE transgene 
and appropriate control littermates, Tyrp1bw/bw mice were bred with DR4 Tg mice.   
Mice were confirmed to have 2 copies of the Tyrp1bw mutation based on 
phenotype (cappuccino colored and confirmed to have at least 1 allelic copy of 
the DR4-IE chimeric transgene using polymerase chain reaction amplification of 
genomic DNA (oligonucleotide primers previously described). The F2 progeny 
yielded 2 experimental groups: Tyrp1bw/bw//DR4+ (Bw) and Tyrp1+/bw//DR4+ (WT) 
C57BL/6 (BL/6), OT-I, and OT-II transgenic (83,84) mice were purchased from 
Jackson Laboratories and used in an age range of 6-10 weeks. 
 
Cell lines.  Murine [B16.F10, MC-38, E.G7; American Type Culture Collection 
(ATCC), Manassas, VA], human tumor lines (397, 526, 624, 1088, 1102, and 
SK23 Mel, provided as a gift from S.A. Rosenberg, Surgery Branch, NCI/NIH) 
and human Epstein Barr virus (EBV)-B cell line (1088 EBV-B) were maintained in 
complete media (CM), as previously described (85). The 1088 Mel stably 
transduced with CIITA was prepared as previously described (79).  Human 
leukocyte antigen (HLA)-DRB1* genotypes of tumor lines used in the following 
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experiments included 397 Mel (0404, 0408), 526 Mel (0401,1401), 624 Mel 
(0401,0701). 1088 Mel and EBV-B (0301,0401), as previously described (86).  
Murine tumors B16.F10 (B16) and MC38 were transduced with the retrovirus 
pLXSN (Clontech, Mountain View, CA) expressing the DR4 transgene (provided 
as a gift from P. Robbins, Surgery Branch, NCI/NIH). 
 
Immunizations.  Experimental mice [Tyrp1bw/bw//DR4+ (Bw) and Tyrp1+/bw//DR4+ 
(WT)] or control mice [OT-I or OT-II] were immunized with 50 µg of protein 
[mTRP-1, hTRP-1 or ovalbumin (OVA)].  Preparation of recombinant mTRP-1 
and hTRP-1 has been previously described (79).  Recombinant full-length OVA 
protein was purchased from Sigma; St Louis, MO.  Proteins were emulsified in 
incomplete Freund's adjuvant (final volume 100 µL), divided equally and 
administered subcutaneously into the rear footpads.  Fourteen days after primary 
vaccination, mice were boosted with the same amount of protein in incomplete 
Freund's adjuvant fluorescent antibody in the same location.  Two weeks after 
the second immunization, inguinal lymph node (LN) cells were extracted and 
assessed for ex vivo reactivity or expanded in culture for subsequent 
experimental assays. 
 
Ex Vivo assays.  Two weeks after the second immunization, LN cells were 
extracted and then assessed for phenotypic expression using fluorochrome-
conjugated antibodies specific for murine CD4 (GK1.5, APC, BD Bioscience, San 
Diego, CA), CD8 (53-6.7, PE, BD Bioscience), CD3 (17A2, PE-Cy5, BD 
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Bioscience), CD25 (7D4, FITC, BD Bioscience), and Foxp3 (FJK-16s, Pacific 
Blue, eBioscience, San Diego, CA). ELISPOT ex vivo assays were performed in 
the following manner: M200 plates (CTL, Shaker Heights, OH) were precoated 
with IFN-γ antibody (R46A2; BD Biosciences) at 4 µg/mL and incubated 
overnight; LN cells (4×105/well) and targets (pulsed 1×105 1088 EBV-B cells) 
were added to wells in triplicate in 200 µL of HL-1 CM (HL-1 Media, Biowhittaker, 
Walkersville, MD, L-glutamine 200 mM; and gentamycin sulfate 50 mg/mL); EBV-
B cells were pulsed the day before (from 12 to 18 h) with peptide (50 µM), protein 
(50 µg/mL) or lysate (105 cell equivalents/well; and prepared as previously 
described, (79).  After a 24-hour coculture, plates were incubated with 
biotinylated IFN-γ antibody (XMG1.2; BD Biosciences) at 2 µg/mL.  The next day 
plates were incubated with streptavidin-alkaline phosphatase (Southern 
Biotechnology, Birmingham, AL) at a 1:1000 dilution for 2 hours, after the 
addition of p-nitroblue tetrazolium chloride-5-bromo-4-chloro-3-indolyl phosphate 
(Thermo Scientific, Rockford, IL); the resulting spots were counted on a 
computer-assisted ELISPOT image analyzer (Immunospot Series I Analyzer, 
CTL).  Monoclonal antibodies (mAbs) were used (at 50 µg/mL) to inhibit the 
recognition by T cells included HB55 (against HLA-DR; IgG2a; ATCC) and W6/32 
(against HLA-A, HLA-B, HLA-C; IgG2a; ATCC). 
 
Generation of established CD4+ T cell lines.  Extracted LN cells from 
immunized mice were cultured in 24-well plates at 5×106 cells per well with 
peptide hTRP-1277–297 at 50 µM (or control class I OVA257–264 at 10 µM or control 
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class II OVA323–339 50 µM).  Twelve days after the first ex vivo stimulation, both 
lines were restimulated with peptide-pulsed, irradiated, syngeneic DR4 Tg 
splenocytes.  Splenocytes were pulsed with hTRP-1277–297 at 50 µM for 3 hours at 
37°C, washed, irradiated with 3000 rads, then added to each T cell culture at a 
10:1 ratio (5×106 APCs per well).  CM containing interleukin (IL)-2 (Chiron, 
Emeryville, CA) at 7.5 cetus units/mL was added 2 days after the stimulation (day 
14).  Multicolor flow cytometry for CD4, CD8, CD25, and Foxp3 T cell expression 
was performed using the mAbs described above.  Lines were stimulated and 
maintained using the same methods every from 10 to 15 days.  To evaluate 
specific T cell reactivity, splenocytes or 1088 EBV-B cells were pulsed for 3 
hours with peptide (at various concentrations) or with recombinant protein 
overnight.  Whole tumor cells (pretreated with IFN-γ × 48h at 200U/mL) or pulsed 
APCs (105 cells per well) were then cocultured with 105 T cells per well in U-
bottom 96-well plates for 24 hours.  The mAbs HB55 and W6/32 were again used 
to block T cell interactions. Culture supernatants were assayed for IFN-γ, IL-4, or 
IL-17 using commercially available enzyme-linked immunosorbent assay (ELISA) 
kits (BD Bioscience). 
 
Tumor treatment and antibody depletion assays.   Six to eight week-old 
female C57BL/6 and DR4 Tg mice were injected intravenously through the tail 
vein with 5×105 B16 melanoma cells, MC-38 or E.G7 tumor cells at 5 animals per 
group (day -4).  Four days later, mice were injected intravenously (day 0) with 
various quantities of T cells generated from immunized OT-1, OT-II, 
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TRP1bw/bw//DR4+, and TRP1+/bw//DR4+ mice.  Twelve days later (day +12), lungs 
were removed, countered stained with India ink and metastases enumerated in a 
blinded fashion (87).  For tumor treatment experiments involving antibody 
depletion, mAbs to murine CD4 (GK1.5), CD8 (53-6.7), and NK and natural killer 
T cell (NKT) (PK136) were purified from hybridoma culture supernatants (ATCC), 
and injected (100 µg) intraperitoneally into host mice at 5 animals per group 
every 3 days beginning 9 days (day -13) before tumor injection.  Treg depletion 
was performed with a single intraperitoneal injection of 400 µg (anti-CD25 PC61 
or control rat IgG) 4 days before tumor implantation (day -8) into 5 experimental 
mice per group.  Depletion analysis by fluorescence-activated cell sorting was 
performed on peripheral blood on the day of adoptive transfer (day 0).  Treatment 
results are shown as standard error of the mean and statistical significance 
between groups was determined by Student t test. 
 
Thymic digestion for mTEC isolation. Thymuses (5-20) were removed from 
experimental mice (optimal age: 6-10 weeks) and placed into ice cold RPMI.  Fat 
and connective tissue was pulled off the lobes with forceps.  All of the lobes were 
separated, nicked with scissors, and placed into a round bottom tube with a 
magnetic stir bar.  10mL of RPMI was added to the tube, and the thymuses were 
agitated with stirring for 10 minutes.  Supernatant was poured off, and then 
enzyme solution 1 was added to the tube (RPMI, Collagenase D [Roche] .125% 
w/v, DNase I [Biomatik] .1% w/v).  The thymus tissue was stirred for 15 minutes 
on a hot plate at 40°C and supernatant was collected and kept on ice.  This 
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digestion step was repeated 3 more times.  Next, the thymus tissue was 
incubated with enzyme solution 2 (RPMI, Collagenase/Disapse [Roche] .125% 
w/v, DNase I .1% w/v) for 15 minutes – or until satisfactorily disaggregated – and 
the supernatant was collected.  The pooled supernatant sample from all digests 
was centrifuged at 470xg for 5 minutes, resuspended in EDTA/FACS buffer (1x 
PBS, 5mM EDTA, 2% FCS, NaN3 .02% w/v) and incubated at 4°C for 10 
minutes.  Next, the cell suspension was poured over a 40µm filter and counted 
with a hemocytometer.  The sample was centrifuged at 470xg for 5 minutes and 
resuspended in MACS buffer (Miltenyi formulation) at 95µL/107 cells.  Magnetic 
anti-CD45 microbeads (Miltenyi) were added to the suspension at 5µL/107 cells.  
From this point onward, the directions for the Miltenyi CD45 kit were followed to 
deplete the sample of CD45+ cells using the appropriate number of LS columns 
with a MACs magnet.  The CD45- fraction was washed and prepared for mTEC 
cell sorting. 
 
mTEC cell sorting.  Cells were acquired on a FACS Vantage or FACS Aria 
sorter using either Cell Quest or FACSDiva software, respectively.  The live 
population was gated based on forward and side scatter parameters.  Cells were 
then sorted on the following gated parameters: CD45- (30-F11, PercpCy5.5, BD 
Biosciences), Ly51- (BP-1, PE, BD Biosciences), Epcam+ (G8.8, APC, 
eBioscience), MHC class II+ (M5/114.15.2, FITC, eBioscience).  
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Confocal microscopy and immunofluorescence.  8-well chamber slides 
(Biomatik) were coated with 1% gelatin for 15 minutes at room temperature.  
Cells were then plated overnight in individual wells with their customary media 
(mTECs were plated in RPMI complete media supplemented with L-glutamine, 
5%).  The following day, culture media was removed, and all samples were fixed 
with 3.7% paraformaldehyde for 15 minutes at room temperature.  After fixing, 
paraformadehyde was pipetted off, and the wells were gently washed three times 
by adding 1x PBS for consecutive 5 minute incubations.  Next, the cells were 
permeabilized by adding methanol for a 3 minute incubation after which cells 
were washed 3 times with 1x PBS.  After washing, each well was coated with 
blocking solution (5% Bovine Serum Albumin & 1% goat serum in 1x PBS) for a 
30 minute incubation.  The blocking solution was removed and cells were 
washed with 1x PBS for five minutes.  1µg anti-TRP-1 Ab (Mel-5, Covance) was 
conjugated via the Alexa Fluor 488 Antibody Labeling Kit (Invitrogen).  Sample 
wells were labeled with 1µg of the conjugated Mel-5 Ab or conjugated Mouse 
IgG2a isotype control Ab and left for 1 hour at room temperature.  All wells were 
washed 3 times with 1x PBS, and cells were left with a residual layer of buffer 
after the final wash.  Finally, immunofluorescent images of the samples were 
acquired on an Olympus FV1000-MPE Confocal/Multiphoton Microscope. 
 
RNA isolation. Cell samples were transferred to RNase-free tubes and 
centrifuged to pellets.  Samples were lysed followed by RNA spin-column 
isolation using either the Qiagen RNeasy Mini kit (when >2x105 cell sample) or 
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RNeasy Micro kit (when <2x105 cell sample).  RNA was either used fresh or 
stored at -80°C for later experimentation.   
 
mRNA amplification.  All mTEC RNA samples were harvested with the RNeasy 
Micro kit (Qiagen) and then linearly amplified with the MessageAmp III RNA 
Amplification Kit (Ambion).  For amplification, 5µL of sample RNA was 
incorporated into a sequence of PCRs according to the manufacturer‟s protocol.  
Afterwards, the amplified samples were conjugated with RNA binding beads, 
washed, and then eluted. 
 
Quantitative real time PCR gene expression assays.  Reverse transcriptase 
(Applied Biosystems, ABS) was utilized according to the manufacturer‟s protocol 
for synthesis of cDNA from mRNA samples.  The cDNA samples were then 
incorporated into quantitative real-time PCR reactions to probe for transcript 
levels of the gene of interest with the following reaction setup: 10µL PCR 
Mastermix (ABS), 1µL gene specific FAM probe (ABS), 5µL cDNA sample, 4µL 
H2O.  Samples were run on a StepOnePlus Real-Time PCR System (ABS) using 
the StepOne v2.1 software in “relative” format with the housekeeping gene β-
actin used as an internal standard for normalization.  Sample results were 
reported as “RQ” values, representing the ratio of transcript with respect to the 
experimental sample defined as „1‟.  Reactions were performed in triplicate and 
standard error was calculated by the software (p < .05).  
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Bone marrow transplant.  Mice with three distinct genotypes – C57BL/6, 
DR4Tg, and Tyrp1bw/bw – were utilized as recipient cohorts with 5 mice per 
cohort.  All subjects were given doxycycline feed on d -3 to reduce bacterial load 
(prior to the subsequent neutropenia from irradiation).  Mice were lethally 
irradiated on d -1 with 900Gy.  On d 0, 7 Trp-1 TCR Tg mice were euthanized; 
femurs were extracted and flushed with 1x PBS to obtain donor bone marrow 
cells.  The donor bone marrow was treated with RBC lysis buffer (Qiagen) to 
remove RBCs and then washed and counted with a hemocytometer.  Cells were 
conjugated with the following 3 biotinylated, monoclonal Abs: anti-CD3, anti-
NK1.1 and anti-CD19 (eBioscience), corresponding to markers on mature T, NK, 
and B cells, respectively.  Strepavidin magnetic beads (Miltenyi) were added to 
the cells to bind to the antibody-coated cells.  The samples were then washed 
and run over a magnetized LS column (Miltenyi) to remove the aforementioned 
mature lymphocyte populations from the donor bone marrow.  The sample was 
resuspended in 1x PBS at 7x106 cells/400µL.  Each recipient mouse received a 
tail vein injection of 400µL of the donor cell suspension. 
 
Transplant analysis.  At 8 weeks, transplanted mice were euthanized.  Their 
thymuses and spleens were removed, homogenized, washed and filtered.  
Samples were Fc blocked and then stained for analysis.  To analyze thymocytes, 
samples were stained with mAbs specific for the TRP-1 transgenic beta chain, 
Vβ14 (14-2, FITC, BD Bioscience) as well as CD4 (APC), CD8 (PercpCy5.5), 
CD25 (PE), Foxp3 (Pacific Blue) (clones previously catalogued in earlier 
32 
 
Methods).  Additionally, samples were stained with Annexin V (PE, eBioscience) 
and mAbs specific for Vβ14, CD4 and CD8 to analyze apoptosis.  Splenocytes 
were stained with mAbs specific for Vβ14, CD4 and CD8 to analyze the presence 
of transgenic T cells in the periphery.   
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RESULTS 
Assessing the T cell immune response to TRP-1277-297 in TRP-1
bw versus WT 
mice ex vivo 
TRP-1bw breeder mice were crossed with DR4 Tg mates (both on a C57BL/6 
background).  Offspring were crossed to produce an F2 generation comprised of 
Tyrp1bw/bw//DR4+ (Bw) and Tyrp1+/bw //DR4+ (WT).  Bw and WT mice were 
vaccinated with recombinant hTRP-1 protein and given a booster vaccination two 
weeks later.  Two weeks following the booster, inguinal lymph nodes were 
removed from each cohort and analyzed by flow cytometry.  Both WT and Bw 
populations were similar in their overall population of CD4+ T cells, 74% vs 83% 
respectively, and Treg cells (CD4
+/CD25+/Foxp3+), 2.2% versus 3.6% respectively 
(Figure 4).  The lymph node cells were also tested for ex-vivo reactivity by 
stimulation with TRP-1 in the form of peptide (100µM), protein (50µg/mL) or cell 
lysate material (105 cell equivalents) pulsed onto DR4+ EBV-B cells.  An 
ELISPOT assay for IFN-γ production was performed to determine the number of 
responding T cells from both the WT and Bw populations in response to these 
various stimuli (Figure 5).  The Bw T cells demonstrated a greater magnitude of 
clonal reactivity to mTRP-1 peptide, human and murine TRP-1 protein, and 
human and murine melanoma cell lysates – B16 and SK23.  Blocking the HLA-
DR molecule with mAb HB55 effectively diminished the number of detectable T 
cells, whereas the HLA class I-specific mAb W6/32 had no effect; this illustrated 
the HLA-class II specificity of the cytokine response.   
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Figure 4.  Prevalence of Tregs in immunized WT and Bw.  LN populations 
obtained after vaccination are comparable in Treg prevalence. TRP1bw//DR4+ (Bw) 
and WT//DR4+ (WT) littermates were immunized twice with recombinant hTRP-
1. Fourteen days after the second immunization, LN cells were harvested and 
stained with antibodies specific for murine CD4, CD8, CD3, CD25, and Foxp3. 
The panels are representative of 3 distinct experiments. 
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Figure 5.  ELISPOT Assay probing response to peptide and tumor.  LN 
cells obtained from TRP-1 KO mice are more potent than WT controls. After 
immunization, LN cells (4x105 per well) were stimulated ex vivo in ELISPOT 
plates with soluble anti-CD3 (2 µg/mL) or DR4+ EBV-B cells (1x105 per well; 
1088 EBV-B) pulsed with peptide (100 µM) or protein (50 µg/mL) or lysate (105 
cell equivalents). LN cells from both groups produce interferon-γ to anti-CD3 
and EBV-B cells pulsed with mTRP-1277–297 or hTRP-1277–297 peptide, hTRP-1 or 
mTRP-1 protein, and to B16 and SK23 Mel lysate. Specific reactivity from both 
groups was blocked with anti-DR antibody, HB55, but not with anti-MHC class I 
antibody, W6/32. No reactivity was observed to either the control peptide (HA306–
318), protein (ovalbumin) or the lysates (MC-38, or 1102 Mel, both negative for 
TRP-1). 
WT//DR4+  Bw//DR4+ 
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Interestingly, both cohorts demonstrated a similar number of responding cells to 
hTRP-1277-297 peptide at the 100µM concentration.  However, differences became 
more apparent when we probed with titrating amounts of human peptide to 
assess the sensitivity of the two populations.  The aforementioned ELISPOT was 
repeated but with a diminishing, log-fold range of peptide concentrations.  
Notably, a 1.5 log-fold greater magnitude of responding T cells was observed at 
half maximal peptide concentration (1µM) for the Bw group compared to the WT 
group (Figure 6).  As before, similar numbers of responding cells were observed 
in both populations at 100µM of TRP-1 peptide, suggesting that the presence of 
self antigen may exert its effects primarily on the higher sensitivity T cells specific 
for that antigen, while not impacting the less sensitive clones.   
 
Phenotypic differences persist between WT and BW TRP-1277-297 specific T 
cells after in vitro expansion 
Having shown a significant difference in the ex-vivo antigen response of CD4+ T 
cells from Bw mice compared to WT, we explored whether cells that were 
expanded from both populations in vitro would demonstrate similar results after 
manipulation in culture.  To address this question, LNs were harvested from 
immunized mice, as in the previous experiments.  After homogenizing the LNs 
and collecting all cells, the populations were stimulated in culture conditions with 
TRP-1277-297 peptide and IL-2; two rounds of stimulation were performed.  
Following the expansion stage, we analyzed the cells by flow cytometry and  
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Figure 6. Ex Vivo ELISPOT titration assay. hTRP-1277–297-specific T cells
from Bw//DR4+ mice are present at a higher frequency. Bw and WT
littermates were immunized with hTRP-1 protein as described in Figure 4. LN
cells were harvested and stimulated (4x105 per well in triplicates) ex vivo with
hTRP-1277–297 pulsed onto DR4
+ EBV-B cells (1x105 per well; 1088 EBV-B) at
titrating (100 to 0.0001µM) peptide concentrations. All experiments were
performed 2 to 3 times with similar results.
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found that, in both groups, greater than 90% were CD4+/CD25+/Foxp3- indicating 
a high level of Teffector cells and a relatively low level of Tregs (Figure 7).  We then 
gauged the response of these populations to TRP-1 by co-culturing them with 
EBV-B cells (APCs) pulsed with titrating levels of TRP-1277-297 peptide.  
Supernatant was collected from the co-cultures and assayed for quantity of IFN-γ 
release by ELISA.  Similar to the previously described ex vivo assay, Bw T cells 
exhibited a more sensitive cytokine response than WT.  This phenomenon 
became most apparent at diminishing levels of antigen where at half maximal 
concentration (100nM), the Bw:WT IFN-γ secretion ratio was 15:1; at 1nM, the 
observed ratio was 25:1 (Figure 8).   
 
CD4+ T cells derived from Bw mice and expanded in vitro respond to 
melanoma cells with greater INF-γ production than those derived from WT 
mice 
After finding that TRP-1 specific CD4+ T cells derived from the antigen-deficient 
Bw population possessed greater sensitivity and potency to their cognate peptide 
epitope verus the WT cells, we next explored their functionality in a more clinical 
context.  Both T cell populations were co-cultured with either recombinant TRP-1 
protein or various melanoma cell lines, and their respective responses were 
assessed with an ELISA that probed IFN-γ secretion (Figure 9).  This design 
allowed for comparing the samples in a setting where antigen processing and 
presentation mechanisms were necessary and also where actual tumors with  
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Figure 7.  Tregs in ex vivo expanded cells. TRP1bw/bw//DR4+ and WT//DR4+ Tg 
littermates were immunized with hTRP-1 protein and expanded in vitro. A, Flow 
cytometric analysis of experimental T cell populations. Both groups of in vitro 
IL-2 expanded WT and KO T cells are equivalently CD4high/CD8dim (panels 1 and 
3) and Treg negative CD4high/CD25high/Foxp3dim (panel 2 and 4).  
WT//DR4+ Bw//DR4+ 
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Figure 8. ELISA comparing Bw and WT T cells at diminishing peptide
concentrations. TRP-1-specific T cells from WT and Bw mice were
expanded in vitro by peptide pulsing (TRP-1277-297) upon LN removal, pulsing
again on d 12, and stimulating with IL-2 on d 14. Cell lines were stimulated
and maintained using the same methods every from 10 to 15 days. The
expanded populations were co-cultured with DR4+ EBV-B cells (1088 EBV-B)
pulsed with titering concentrations of hTRP-1277–297. Significant differences in
potency of IFN-γ release were observed between the groups with consistently
higher concentrations secreted by Bw T cells over a range of peptide
concentrations.
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Figure 9.  ELISA demonstrating IFN-γ release in response to antigen and 
tumor.  CD4+ T-cells derived from TRP-1-deficient hosts (Bw) release high levels 
of cytokine in response to intact melanoma. CD4+ T cells from WT and Bw react 
differentially react to both the TRP-1 peptide and the recombinant protein when 
pulsed on DR4+ targets (DR4 Tg splenocytes), but not when pulsed onto DR4- 
antigen presenting cells (C57BL/6 splenocytes, I-Ab +). No reactivity was observed 
to control protein ovalbumin. Specific reactivity was also observed to both HLA-
DR4+ and TRP-1+ human melanomas (526 and 624 Mel pretreated with IFN-γ; 
and 1088 Mel stably transduced with CIITA) and to the murine melanoma B16-
DR4 (B16 stably transduced with HLA-DRB1*0401). No reactivity was observed 
against control tumor B16 (DR4-). Recognition of B16-DR4 was blocked with 
monoclonal antibody HB55 (anti-class II), but not with W6/32 (anti-class I). 
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endogenous antigen levels could be tested against the reactive cells.  When 
pulsing recombinant TRP-1 protein onto DR4+ Tg splenocytes, both T cell 
populations demonstrated reactivity but with a clear differential in quantity of 
cytokine released.  Additionally, pulsing of BL/6 (DR4-negative) splenocytes 
elicited no reactivity in either T cell population, illustrating the specificity of the 
277-297 epitope for the DR4 restriction element.  To assess the response 
against tumor cells, the TRP-1 positive human melanomas, 526 Mel and 624 
Mel, as well as murine B16 melanoma transduced with the DR4 gene were all 
included in separate co-cultures with the T cell populations.  Bw-derived cells 
exhibited a more than 20-fold greater potency of IFN-γ production in response to 
the two human tumor lines versus WT-derived cells as well as a greater 
response to the B16-DR4 line expressing murine TRP-1.  Neither T cell 
population secreted significant cytokine against 397 Mel, a DR4 negative 
melanoma line.  Moreover, inclusion of HB55, an anti-class II Ab, abrogated the 
response to B16 DR4 melanoma, again demonstrating class II specificity for the 
277-297 epitope (Figure 9). 
 
Cytokine analysis of cells derived from TRP-1 vaccinated Bw and WT mice 
reveals a polarized Th1 profile 
The Trp-1-specific T cells from Bw and WT vaccinated mice were cultured for 3 
weeks in vitro to expand their numbers for assays and immunotherapy 
experiments.  Given the possibility of cells undergoing phenotypic changes while 
in culture, it was important to characterize the cytokine secretion profile of the 
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populations following the artificial expansion.  The T cells were co-cultured with 
TRP-1277-297 peptide-pulsed APCs (EBV-B cells) as well as antigen positive B16-
DR4 cells.  Additional negative control co-cultures included HA peptide pulsed 
APCs as well as MC38-DR4, a TRP-1 negative carcinoma line.  Supernatants 
were collected from the co-cultures and characterized by ELISA for levels of IFN- 
γ, IL-4 and IL-17.   The levels of IL-4 and IL-17 did not rise above background for 
any of the co-culture conditions suggesting little to no presence of Th2 or Th17 
cells.  However, IFN- γ was released in substantial amounts (and at higher levels 
by the Bw mice) in the peptide pulsed and antigen positive co-cultures.  This 
finding characterizes the T cell response to TRP-1 as consistently polarized 
towards T helper type 1 (Figure 10). 
 
High-avidity TRP-1 specific CD4+ T cells derived from Bw hosts mediate 
tumor destruction  
Given that Bw mice immunized with TRP-1 produced a greater magnitude of 
CD4+ T-cells which secreted higher concentrations of cytokine per cell than WT 
in response to antigen, we sought to determine if the Bw T cells were also more 
effective at eradicating tumor in vivo.  Additionally, we assessed whether the 
treatment effect was antigen-specific, DR4-restricted and also whether it was 
mediated by direct or indirect recognition of tumor. To test these questions, we  
took advantage of the unique genetic differences in MHC expression on both the 
tumor cells (DR4-) and host APCs (DR4+), as well as the restriction elements that  
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Figure 10.  Cytokine release profile of TRP-1 specific T cells.  CD4+ T cells 
from both groups exhibit a Th1 cytokine profile (IFN-γ production, but none to 
IL-4 or IL-17A by enzyme-linked immunosorbent assay) in response to specific 
peptide and tumor (B16-DR4, but not MC-38-DR4). All experiments were 
performed 2 to 3 times with similar results. EBV-B indicates Epstein Barr virus-
B; IL, isoleucine; TRP, tyrosinase-related protein. 
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mediate the reactivity of both host CD8+ T cells (Kb/Db+) and the adoptively 
transferred CD4+ T cell treatment population (DR4+).  A general schematic for all 
tumor treatment experiments is shown in Figure 11. 
 
We initially performed a 4-day lung metastasis treatment experiment using 3 
different tumor-bearing hosts: (1) B16 (TRP-1+) lung metastases in DR4 Tg 
(DR4+); (2) B16 lung metastases in C57BL/6 (DR4-); and (3) MC38 (TRP-1-) lung 
metastases in DR4 Tg.  Mice received intravenous injection of B16 melanoma (or 
control MC38 tumor) which metastasizes to the lungs, engrafting as quantifiable 
tumor nodules.  T cells were obtained from the lymph nodes of WT and Bw mice 
after immunization then expanded in vitro and adoptively transferred (107 cells 
per mouse) into tumor-bearing recipients. Importantly, the donor populations from 
WT and Bw had statistically similar percentages of CD4+ T cells including a small 
subpopulation of Treg cells.  A third cohort of tumor bearing mice received control 
OVA-specific CD4+ T cells which were obtained from OT-II mice following an 
analogous immunization and in vitro expansion process with the OVA323–339 
epitope (83).  We observed a significant difference in treatment effect using T 
cells obtained from Bw mice (mean=5 lung metastases; P=0.0006 using a 2-
tailed Student t-test) versus WT littermates (mean=68 lung metastases) versus 
control OVA specific CD4s (mean=156 lung metastases) in DR4 Tg recipients 
bearing B16 lung metastases (Figure 12). This result was contrasted with the 
complete loss of any treatment effect (mean ≥ 150 lung metastases for all  
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Figure 11.  Schema for adoptive transfer of TRP-1 specific T cells.  Recipient 
mice were depleted of specific immune cell populations with monoclonal Abs.  
On d –4, the mice received i.v. injection of B16 melanoma.  At d 0, 107 T cells 
from each experimental population was adoptively transferred into its respective 
tumor-bearing mouse cohort.  12 days later, lungs were removed from all the 
tumor-bearing mice, and metastases were counted in a double-blind fashion. 
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Figure 12. Melanoma treatment is antigen-specific and DR4 restricted.  
Expanded T cells were adoptively transferred (107 per mouse) into three different 
tumor-bearing hosts at 5 mice per group: (1) B16 (TRP-1+) lung metastases in 
DR4 transgenics (DR4+); (2) B16 lung metastases in C57BL/6 mice (DR4-); (3) 
MC38 (TRP-1-) lung metastases in DR4 transgenics.  Each group had been 
previously intravenous tail vein inoculated with tumor.  CD4+ T cells derived from 
the TRP-1Bw//DR4+ mice nearly fully eradicate the 4-day lung metastases (mean 
= 5; P = 0.0006 using a 2-tailed Student t test) when compared with littermate 
(WT) controls (mean = 68) and control OVA-specific CD4+ T cells (mean: 156).  
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treatment groups) in mice bearing our control, antigen-deficient tumor cell line 
(MC38) or in recipient mice lacking the specific restriction element (C57BL/6 
mice; DR4-).  Unlike other models of adoptive transfer (88,89), exogenous IL-2 
was not administered, and recipient animals were neither vaccinated nor 
irradiated for these experiments. These results confirmed that the treatment 
effect was both melanoma-specific and restricted by host DR4 expression. 
 
The TRP-1-Specific CD4+ Donor T Cells Mediate Tumor Treatment Via Host 
CD8+ T Cells 
To more specifically determine if the treatment effect was mediated by individual 
T cell subset populations (from either the host or those transferred), we 
performed a similar adoptive transfer experiment using CD4+ T-cells derived only 
from Bw mice.  The B16 tumor-bearing recipient mice were first depleted of 
individual effector cell subsets (CD4, CD8, NK, and NKT) before adoptive 
transfer.  Elimination of >95% of each population was confirmed by flow 
cytometry. The treatment effect was entirely abrogated after host CD8+ T cell 
depletion with no significant difference between the CD8 depletion group and the 
OVA control group (mean=121 vs. 127 lung metastases; P=0.106).  Moreover, 
we excluded the contribution of other host components by observing a nearly 
complete and equivalent treatment effect after host CD4 and NK/NKT depletion 
(mean=7 vs. 4 lung metastases; P=0.128) or with control rat IgG administration 
(Figure 13). These results identified endogenous CD8+ cells as the major 
mediators of tumor treatment. 
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Figure 13.  Role of endogenous CD8+ T cells in immunotherapy.  Treatment 
of B16 lung metastases is dependent upon host CD8+ T cells.  Tumor-bearing 
(B16 only) DR4 Tg mice were depleted of individual effector-cell subsets (CD4, 
CD8, natural killer and natural killer T cell) after IP injection of monoclonal 
antibodies before adoptive transfer of CD4+ T cells derived from TRP1Bw//DR4+ 
mice. Control OVA-specific CD4+ T cells were used to measure the nonspecific 
effects of adoptive transfer. Each experimental arm involved 5 mice per group. 
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High-avidity CD4+ T cells derived from Bw mice overpower host Tregs in 
effecting tumor destruction 
A preponderance of animal and clinical studies have demonstrated that the 
elimination of Tregs can break self-tolerance, enhance antitumor immunity, and 
improve the antitumor effects of both cancer vaccines and adoptively transferred 
cells (90,91).  We hypothesized, therefore, that depletion of host Tregs would 
improve the treatment effect of adoptively transferred CD4+ T cells.  To address 
this question, we incorporated an established protocol (92) using an anti-CD25 
mAb (PC61) capable of depleting CD4+/CD25+/Foxp3+ Tregs.  The extent of 
depletion was determined by flow cytometry on the day of adoptive transfer from 
peripheral blood samples.  This protocol has shown no effect on host CD25- cells 
(both CD8+ and NK+), nor any suppressive effect on members of the IL-2 
cytokine family including IL-21 (93).  To more precisely measure the depletion 
impact on treatment, we adoptively transferred titered numbers of CD4+ T cells 
derived from Bw mice in a side-by-side comparison with those from control OVA-
specific cells (CD4+/CD25+, as determined by flow cytometry, Figure 14).  
Although we found a decreasing treatment effect with diminishing numbers (107, 
106, and 105) of infused T cells, we also found that pretreatment with PC61 had 
no demonstrable impact on the overall efficacy when compared with the control 
IgG administration.  This result was contrasted by a demonstrable treatment 
effect that favored Treg elimination before adoptive transfer of the lower avidity 
WT TRP-1 specific T cells (107 cells only).  As in the prior experiment, we found  
 
51 
 
 
 
Figure 14.  Treg status of transplanted mice.  Flow cytometric analysis obtained 
from peripheral blood samples on the day of adoptive transfer of host T reg status 
(CD4+/CD25+/Foxp3+) after depletion with control rat IgG (panel 1) or with PC61 
(panel 2), respectively. Flow cytometric analysis of control in vitro expanded OT-
II and OT-I cells are CD4+//CD25high (panel 3) and CD8high/CD25high (panel 4), 
respectively; the panels are representative of three distinct experiments. 
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no treatment effect with the control OVA-specific CD4+/CD25+ T cell transfer 
(Figure 15). 
 
Although neutralizing levels of PC61 appeared to have no functional inhibitory 
effect on the subsequently infused CD4+/CD25+ T cell population, a finding noted 
by other investigators (94-96), that issue still remained unclear for our studies.  
To control for the confounding effects of residual circulating CD25 antibodies on 
the adoptive transfer cell population and gauge the relative impact of Treg 
depletion on antitumor responses, we infused various titers of CD8+/CD25+ Kb-
restricted OVA-specific T cells (generated with 3 rounds of in vitro stimulation 
using peptide and IL-2) into C57BL/6 mice implanted with the OVA-expressing 
thymoma cell line E.G7.  Unlike high avidity CD4+ T cells, OVA-specific CD8+ T 
cells had statistically greater (P=0.0002 at 106 and P=0.0001 at 105 cells infused) 
therapeutic efficacy when host animals were depleted of Tregs before adoptive 
transfer when compared with control depletion (rat IgG) or control cells (TRP-1-
specific CD4s) (Figure 15). These results show that high avidity TRP-1-specific 
CD4+ T cells were maximally effective against established tumor regardless of 
host Treg status. 
 
Histology of Bw skin compared to WT and Mitf-/- samples 
The previously published findings on the Bw mouse were suggestive of TRP-1 
antigen deficiency, though not conclusive.  The distinct cappuccino coat color  
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Figure 15.  The effect of Treg depletion on tumor treatment efficacy.  
Treatment of B16 lung metastases is unaffected by Treg depletion.  Tumor-
bearing (B16 only) DR4 Tg mice were depleted of Tregs after IP injection of 
monoclonal antibody PC61 before adoptive transfer.  CD4+ T cells derived from 
KO mice and control OT-II mice were transferred at titering concentrations (107, 
106, and 105). CD4+ T cells derived from TRP-1 WT mice were transferred at 107 
cells only.  Pretreatment with PC61 has no impact on treatment when compared 
with control rat IgG administration using KO cells when compared with WT cells.  
Also, the cohort adoptively transferred with OVA-specific CD4+ T cells gained no 
treatment effect. C, OVA-specific CD8+/CD25+ T cells more effectively eradicate 
established tumor in hosts depleted of Tregs.  Tumor-bearing (E.G7 only) C57BL/6 
mice were similarly depleted of Tregs before adoptive transfer. CD8
+ T cells 
derived from OT-I mice and control TRP-1-specific CD4‟s were adoptively 
transferred at titering concentrations. Pretreatment with PC61 significantly 
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improved the overall treatment effect at both 106 and 105 cells infused when 
compared with control rat IgG. No significant treatment effect was observed 
using control TRP-1- specific CD4+ T cells. Each experimental arm involved 5 
mice per group, and all experiments were performed at least 2 to 3 times with 
similar results. Ig indicates immunoglobulin; OVA ovalbumin; TRP, tyrosinase-
related protein. 
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phenotype of these mice points to a defect in melanin production.  Furthermore, 
molecular analysis of whole skin homogenates (which are dominated by 
keratinocytes, not melanocytes) via RT-PCR failed to amplify a detectable level 
of TRP-1 RNA transcript (97).  Given that TRP-1 expression is primarily confined 
to the melanocyte population, a cell that is relatively sparse in whole skin, these 
results were limited in their ability to precisely define TRP-1 expression in the Bw 
host.  A primary objective of this project was to probe the role of tolerance in 
manifesting the differential immune response between the BL/6 and TPR-1bw 
cohorts.  Therefore, it was necessary to more thoroughly analyze skin histology 
and melanocyte characteristics of the TRP-1 antigen in the Bw mouse.  First, 
skin samples were taken in sections from the neck and upper back of WT, Bw, 
and Mitf-/- mice and sliced for immunohistochemistry.  The slices were stained 
with S100 Ab, a probe for cells of neural crest origin including melanocytes.  The 
result from our WT sample illustrated a classic histological pattern of 
melanocytes in the skin with cell clusters staining positive, particularly around the 
epithelium of the hair follicle (Figure 16).  Conversely, the Mitf-/- skin sample was 
devoid of melanocytes with no detectable S100 staining anywhere around the 
hair follicles or throughout the epithelium.  This result was consistent with 
findings in the literature that show mice without functional Mitf lack viable 
melanocyte precursors known as melanoblasts (44). Notably, the Bw sample was 
sparsely stained by S100 with more isolated, punctuate areas reading positive.  
The cappuccino coat color of Bw mice is consistent with diminished or impaired  
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Figure 16.  Immunohistochemistry of skin sections from WT, Mitf-/- and Bw.  
Skin was collected from each respective mouse and paraffin embedded.  
Samples were stained with S100 Ab and immunohistochemistry was performed.  
A. WT skin sample - ovals encompass the brown-staining clusters surrounding 
hair follicles in a typical pattern for melanocytes. B. Mitf-/- skin sample - No 
staining is evident as these mice lack viable melanocytes.  C. Bw skin sample - 
Individual melanocytes are indicated by arrows. Bw mice apparently have 
detectable melanocytes in the vicinity of hair follicles but display drastically 
reduced density compared to the WT.  (The smudge staining is consistent with 
sebaceous glands.) 
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melanin production which may correspond to a defect at the gene level resulting 
in TRP-1 deficiency; based on S100 levels, a defect at the tissue level (fewer 
melanocytes) may also explain this.   
 
Analysis of TRP-1 expression in Bw and WT melanocytes 
A more thorough analysis was conducted to characterize the tissue specific TRP-
1 levels in Bw mice and gauge the relative levels with respect to WT mice.  To do 
this, melanocytes were cultivated from neonatal Bw offspring for gene and 
protein expression assays.  Whole skin was collected from a neonatal cohort and 
disaggregated in media.  The epidermis was removed from the dermal layer then 
homogenized and cultured with growth factors to promote melanocyte 
differentiation and proliferation.  We performed confocal microscopy to probe for 
protein level expression of gp100 and TRP-1 in the Melan-a and 5-2 lines.  Cells 
were cultured in chamber slide wells and then incubated with either hPEP7 (anti-
gp100) or MEL5 (anti-TRP-1) primary Abs followed by FITC-labeled secondary 
Abs.  Immunofluorescence imaging revealed detectable gp100 levels dispersed 
in a similar pattern within both the Melan-a and 5-2 populations (Figure 17).  
Importantly, the MEL5 staining showed substantial levels of TRP-1 in the Melan-
a cells but no detectable protein within the 5-2 population, further validating the 
gene expression results and solidly confirming TRP-1 protein deficiency in Bw 
mice (Figure 17). 
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Figure 17.  Confocal microscopy of melanocytes. Immunofluorescence 
staining of a C57BL/6 melanocyte line (Melan-a) and a TRP-1bw melanocyte line 
demonstrates the presence of a characteristic MDA, gp100, and the absence of 
detectable TRP-1 in the Bw population. 
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Medullary thymic epithelial cells of WT mice express detectable levels of 
TRP-1 
Mouse studies have illustrated the significance of peripheral antigen expression 
in medullary thymic epithelial cells for mediating central T cell tolerance to self 
antigens.  As previously described, artificial models with OVA and HA as well as 
endocrine related antigens, such as insulin, have all agreed on this concept.  In 
consideration of the potential role of central tolerance in the context of the TRP-1 
antigen, we isolated murine medullary thymic epithelial cells (mTECs) for gene 
expression analysis.  Sample thymuses were harvested and digested, depleted 
of CD45 cells via MACS and sorted for the CD45- Ly51- MHC Class II+ EPCAM+ 
fraction.  The yield from this protocol over multiple mTEC collections was 
between 10-20% of the input CD45 depleted population (Figure 18).  Additionally, 
mTECs were isolated for analysis by confocal microscopy.  A sorted cell 
suspension was plated in a chamber slide side-by-side with B16 melanoma 
(TRP-1 positive) and E89 melanoma (TRP-1 negative).  All cells were stained 
with MEL-5 Ab, labeled with AlexaFluor 488 and then imaged.  Microscopy 
revealed substantial levels of TRP-1 in the cytoplasm of the B16 cells, whereas 
the E89 population showed only weak background staining.  Most importantly, a 
subset within the mTEC population stained at a detectable level pointing to a 
baseline level of TRP-1 protein expression within the thymus (Figure 19). 
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Figure 18.  Flow sorting schema for collection of mTECs.  mTECs were 
harvested by digesting thymic tissue into homogenates, then depleting samples 
of CD45+ cells with anti-CD45 Miltenyi MACS beads.  The typical yield of WT 
mTECs from total cells placed into the sorter was 10-20%. 
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Figure 19.  Confocal microscopy of mTECs.  Cells were plated in 8-well 
chamber slides overnight.  Each sample was fixed with 4% paraformaldehyde 
and permeabilized with methanol.  A. Wells were stained with Mel-5 Ab 
conjugated with AlexaFluor 488 fluorophore.  B16 melanoma stained positive, 
and E89 was negative, as expected.  The mTEC sample was interspersed with 
dim positive staining cells.  B. (Separate experiment from A) Top Panels:  
mTECs stained with isotype conjugated with AlexaFluor 488 (Mouse IgG2a).  
Left side is light microscopy view, and right side is immmunofluorescent view.  
No apparent isotype staining was detected.  Bottom Panels: mTECs stained with 
Mel-5 Ab conjugated with AlexaFluor 488. 
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Transcription factor expression in mTECs (Aire and Mitf) 
Clarifying the transcriptional control of promiscuous antigen expression in 
mTECs has remained elusive.  The previously described studies in the literature 
examined various transcription factors, cell signaling molecules and chromatin 
modifiers as contributing factors.  While certain causal relationships have been 
established (particularly Aire promotion of endocrine gene expression), so far no 
unifying mechanism has emerged.  Having already discovered that TRP-1 is 
expressed in mTECs, we explored the question of what promotes the Tyrp1 gene 
in the mTEC population.  One target of interest was the Aire molecule, which has 
been associated with mTEC development and promiscuous expression of insulin.  
The second target of interest was mMitf, which is a core transcription factor 
employed by melanocytes to promote expression of MDAs, including TRP-1.  To 
test these questions, we acquired Aire-/- and Mitf-/- mice (Figure 20), and isolated 
their mTECs for analysis (Figure 21).  Before proceeding, we confirmed the 
knockout genotype of the Aire-/- mice received from Jackson Labs; Aire-/- mTEC 
RNA as well as WT mTEC RNA was amplified in an RT-PCR reaction with 
primers flanking the region as done by Anderson et al. (98).  The PCR products 
were run on a 1% agarose gel with a 1kb ladder to confirm the band sizes.  In the 
lanes containing the Aire product, the WT sample showed up in a size- 
appropriate position, and the Aire-/- sample appeared in the appropriate smaller 
size position on the gel, corresponding to the knockout size (Figure 22). Next, we 
performed a qRT-PCR with all 4 mTEC samples (WT, Bw, Aire-/-, Mitf-/-) to assess 
TRP-1 expression.  
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Figure 20.  Illustration of coat color phenotypes.  Three populations of mice 
were utilized for skin histology, mTEC preparations and gene analysis: WT, Bw, 
and MITF-/-.  WT and Aire-/- mice have a traditional black coat color whereas Bw 
mice demonstrate a lighter cappuccino phenotype.  Mitf-/- mice, lacking viable 
melanoblasts early in development, have no melanocytes and are consequently 
white.  
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Figure 21.  FACS sorting of mTECs from Bw, Mitf-/- and Aire-/- mice.    Sorting 
schemas and final yields are noted for each respective sample.  Mitf -/- sample 
prep yielded lower percentage of mTECs from the population compared to WT, 
Bw and Aire-/-. 
 
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.  RT-PCR analysis for Aire expression.  mTEC RNA samples from 
WT and Aire-/- were amplified to confirm the size differential expected between the 
two samples.  Aire-/- were generated by a truncation between exon 2 and 3.  
Samples were amplified with primers flanking the proximal upstream and 
downstream region of the exon2/3 truncation and the products were run on a 1% 
agarose gel. 
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Interestingly, the Aire-/- background showed elevated levels of TRP-1 transcript 
compared to WT by a 7-fold magnitude (Figure 23).  Also, we found a 
concomitant elevation of Mitf expression in the Aire-/- mTECs, with substantially 
higher transcript levels – a 450-fold increase compared to the WT (Figure 24).  
The absence of functional Aire in the Aire-/- mice possibly de-repressed one or 
both genes resulting in their noticeable increase. 
 
The data derived from the Mitf-/- sample was also noteworthy.  First, when 
performing the mTEC isolation procedure, we observed a substantially 
diminished cell yield as a percentage of the total.  Whereas an mTEC harvest 
from WT and the other murine populations yielded in the range of 10-20% of the 
total cell population fed into the sort, the mTEC yield from Mitf-/- mice was closer 
to 1%, an apparent log-fold decrease compared to WT (Figure 25).  Mitf has a 
broad, diverse role as a developmental transcription factor with a multitude of 
isoforms distributed amongst various tissue types.  These results may imply a 
role for Mitf in mTEC development. The 4-sample qRT-PCR data was also 
suggestive in this regard.  We noted a log-fold reduction in Aire transcript levels 
expressed in the Mitf-/- samples compared to the WT population (Figure 26).  As 
Aire is an important transcription factor in mTEC differentiation, there could be a 
causative link between these findings.  Finally, we found that TRP-1 transcript 
levels were not diminished in the Mitf-/- sample compared to the WT sample, 
suggesting that, in mTECs, TRP-1 expression occurs independently of the Mitf 
transcription factor (Figure 23).   
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.  Gene expression analysis of TRP-1 by mTECs.  qRT-PCR was 
peformed comparing the mTEC RNA samples from WT, Bw, Aire-/- and Mitf-/- 
mice.  Samples were probed for Insulin expression and results were normalized 
to β-actin expression.  The results showed the expected loss of Insulin 
expression in Aire-/- mice.  Additionally mTECs from MITF-/- mice express log-fold 
lower fold lower levels of Insulin compared to WT sample.   
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Figure 24.  qRT-PCR of mTECs for Mitf expression.  qRT-PCR was peformed 
comparing the mTEC RNA samples from WT, Bw, Aire-/- and Mitf-/- mice.  Samples 
were probed for MITF expression and results were normalized to β-actin 
expression.  The results showed a substantial elevation in Mitf expression in the 
Aire-/- sample.   
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Figure 25.  Gene expression analysis of HPRT by mTECs.  qRT-PCR was 
peformed comparing the mTEC samples from WT, Bw, Aire-/- and Mitf-/- mice.  
HPRT, considered an endogenous housekeeping gene, was probed to assess 
internal variation among the four samples.  Samples were normalized to β-actin 
expression. 
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Figure 26.  Gene expression analysis of Aire.  qRT-PCR was peformed 
comparing the mTEC RNA samples from WT, Bw, Aire-/- and Mitf-/- mice.  Samples 
were probed for Aire expression and results were normalized to β-actin 
expression.  The results revealed that mTECs from MITF-/- mice express log-fold 
lower levels of Aire compared to WT sample.   
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Thymocyte Analysis of WT, Bw, and DR4+ Tg mice transplanted with TRP-1 
TCR Tg bone marrow  
To test the impact of central tolerance on the TRP-1-specific T cell repertoire, we 
performed bone marrow transplants into WT and Bw mice - antigen high and 
antigen-deficient backgrounds, respectively.  A third cohort of DR4+ Tg mice 
(murine MHC class II-, HLA DR4+) was incorporated to control for the MHC class 
II restriction element.  A TRP-1-specific TCR transgenic mouse, previously 
generated by Restifo and colleagues on a C57BL/6 background, was utilized as 
the donor bone marrow population (88,99).  The transgene encodes an I-Ab 
restricted TCR that recognizes the murine TRP-1113-127 epitope.  Following lethal 
irradiation, the WT and Bw cohorts were i.v. injected with TCR Tg donor bone 
marrow that was previously depleted of mature lymphoid populations.  The 
recipient mice were then given 6 weeks for engraftment and hematopoietic 
reconstitution.  Thereafter, we analyzed the thymocyte populations of the two 
cohorts to probe for any tolerizing pressure on the TCR Tg population as 
assessed by cell prevalence or apoptosis.  Samples were stained with anti-Vβ14 
Ab to identify the cells expressing the TRP-1 specific TCR (Figure 27).  Looking 
at single positive thymocytes, we found a similar distribution of total SP CD4+ 
cells in the WT, Bw, and DR4 recipients between 10-12% of total thymocytes.  
Within just the SP subpopulation, we calculated the percentage of Vβ14+ 
thymocytes.  In that category, there was no statistical difference between the 
three recipient populations with all showing transgene expression in about 42-  
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Figure 27.  Thymocyte analysis of TRP-1 TCR Tg bone marrow transplants.  
WT and Bw mice were lethally irradiated then transplanted with 6x106 BM cells 
from TRP-1 TCR Tg mice.  Following engraftment, thymuses were harvested 
from recipient mice.  Samples were stained with anti-CD8, anti-CD4, Anti-Vβ14 
and Annexin V and data acquired by FACS.  Samples were analyzed for the 
CD4+ SP compartment, the Vβ14 positive and negative subsets, as well as the 
percentage cells positive for an apoptosis marker. 
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44% of CD4+ SP cells (Figure 28).  Finally, we assessed apoptosis statistics for 
the SP CD4+ thymocytes (both Vβ14+ and Vβ14-) based on percentage positive 
for Annexin V (Figure 29).  In all 3 recipient populations the percentage of cells 
staining for Annexin V ranged from 6-7% for both Vβ14+ and Vβ14- with no 
statistical differences noted between transgene expressing versus transgene 
non-expressing thymocytes or across the three murine populations (Figure 29). 
 
Splenocyte analysis of mice transplanted with TRP-1 TCR Tg bone marrow 
In addition to monitoring thymocyte development of TRP-1 specific T cells, we 
also compared the peripheral compartment by analyzing splenocytes of the WT, 
Bw, and DR4 recipients.  Cells were gated on CD4+ and then either Vβ14+ and 
Vβ14- to analyze the prevalence of transgene expressing and non transgene 
expressing peripheral T cells (Figure 30)  The prevalence of Vβ14+ expressors in 
the CD4+ population was 44% in the WT, 50% in the Bw, and 51% in the DR4 
population.  The differences among mouse populations were not statistically 
distinguishable. 
 
Gene expression analysis of DCs from WT, Bw, and Mitf-/- mice compared 
to WT mTECs  
In addition to cTECs and mTECs, dendritic cells also contribute to the thymic 
education process.  They present MHC class II complexes which engage and 
positively select thymocytes.  Also, data reported by Bevan with MHC mismatch  
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Figure 28.  Summary of thymocyte populations in transplant recipients.  
Column 1: Percentage of total thymocytes that were SP CD4+.  Column 2: 
Percentage of SP CD4+ thymocytes that were V14+.  Column 3: Percentage of SP 
CD4+ Vβ14- thymocytes positive for Annexin V.  Column 4: Percentage of SP 
CD4+ Vβ14+.  Data represents averages of at least 4 mice/group. 
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Figure 29.  Splenocyte analysis of TRP-1 TCR transplant recipients.  Top 
panel: Peripheral T cells were analyzed on the CD4+ cells and determiningd the 
percentage Vβ14- versus Vβ14+.  Bottom panel: WT recipients had approximately 
44% transgene positive T cells compared to 50% and 51% in Bw and DR4, 
respetively; however, the differences among the 3 groups were not statistically 
significant. 
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Figure 30.  Splenocyte analysis of TRP-1 TCR transplant recipients. Top 
panel: Peripheral T cells were analyzed on the CD4+ cells and determining the 
percentage Vβ14- versus Vβ14+.  Bottom panel: WT recipients had approximately 
44% transgene positive T cells compared to 50% and 51% in Bw and DR4, 
respetively; however, the differences among the 3 groups were not statistically 
significant. 
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experiments on the OT-II and Ova antigen transgenic model suggests that DCs 
play a definitive role in negative selection of SP CD4+ thymocytes (100).  We 
performed a pilot experiment with isolates of thymic, splenic and lymph node 
DCs from mice on a C57BL/6 background to analyze TRP-1 gene expression in 
these populations (Figure 31). 
 
The data generated is from a preliminary experiment with samples that were not 
derived from a uniform mouse population (with thymic tissue from a DR4 Tg 
C57BL/6 background).  DCs were sorted by staining the cell homogenates with 
anti-MHC class II and anti-CD11c Abs and collecting the double positive 
population.  RNA was then isolated from the sorted cells and reverse-transcribed 
into cDNA for qRT-PCR.  The assay analyzed 3 DC samples and 1 WT mTEC 
sample to probe for relative gene expression of TRP-1.  Notably, the results 
showed that DCs expressed TRP-1 in the range of the WT mTEC sample (Figure 
32).  Given the interest in the contribution of DCs to thymocyte selection, these 
findings expand the inquiry into the source of promiscuous antigens in the 
thymus.  The current paradigm in the literature is that DCs acquire exogenous 
antigens in their vicinity, and in the thymus, mTECs are the local source of 
antigens.   
 
 
 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31.  Dendritic cells sorted from Thymus, Lymph nodes, and Spleen.  
Respective tissues were homogenized and stained with anti-MHC class II and 
anti-cd11c Abs.  The double positive DC population was collected from each 
sample with a yield between 0.4-1.4% of total cells. 
  
 
 
 
 
 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32.  qRT-PCR assessing TRP-1 expression in DCs.  RNA from the DC 
samples described in Figure 29 as well as WT mTECs analyzed in a quantitative 
assay to compare relative TRP-1 expression (normalized to β-actin).  
Interestingly, all 3 DC populations showed comparable levels of TRP-1 to the WT 
mTEC population. 
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DISCUSSION 
Chapter 1 
The first aim of this project focused on optimizing a novel T cell based 
immunotherapeutic approach to melanoma in a mouse model.  Over the past 20 
years, several such immunotherapy studies have relied on the unilateral 
activation or delivery of CD8+ T cells specific for tumor antigens.  Although these 
efforts have clarified basic principles of cancer immunotherapy, the clinical 
outcomes have generally been disappointing.  The rationale behind  studies has 
been based several factors including: the availability of known immunogenic 
MHC class I epitopes; the high frequency of 1 particular class I allele (HLA-
A*0201) in melanoma patients (50%); the straightforward assays used to 
measure class I-restricted immune responses; the relative ease in cultivating 
CD8+ T cells compared with their CD4+ T cell counterparts; the widespread MHC 
class I expression on the tumor surface; and the counterproductive actions of 
regulatory T cell activation within the CD4+ population (101).  Given the many 
practical reasons for utilizing CD8+ T cells, we questioned the fundamental T cell 
response itself and also expanded the focus to the CD4+ population as a 
potential role player in immunotherapy applications. 
 
Our initial experiments set out to characterize the immunogenicity of the 
melanoma antigen, TRP-1, as both a self and foreign moiety by using WT and 
antigen deficient (Bw) hosts.  To test this question, vaccination experiments with 
TRP-1 protein were performed to assess immune targeting of a previously 
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identified HLA-DR4-restricted epitope, TRP-1277-297.  We focused on comparing 
and contrasting the intensity of the T cell response to this antigen within both 
hosts.   Using an ELISPOT assay, we tested reactivity to exogenously loaded 
antigen over a log-fold range of peptide concentrations.  At the highest 
concentration of peptide, no difference in T cell frequency was observed.  
However, at diminishing levels, we found a significantly more abundant 
population of responding T cells from the antigen-deficient host, Bw.  Whereas 
the number of WT responders sharply tapered off over the first two logs, the Bw 
population persistently responded with cytokine secretion, even at a three-fold 
log decrease in peptide concentration.  Overall, our findings demonstrated that 
systemic expression of TRP-1 (WT) markedly alters the functionality of the 
corresponding antigen specific T cell repertoire.  These results suggested that 
tolerance to TRP-1 does not result in the complete loss of autoreactive T cells, 
but does significantly dampen the overall potency of the host‟s antigen-specific 
population manifesting in fewer and lower sensitivity clones as seen in the WT 
population.  This same trend was observed after expanding the TRP-1 specific T 
cells in vitro and assaying both populations. 
 
Despite the emphasis on CD8+ T cell responses by previous immunotherapy 
clinical trials, there has been mounting data to support the critical role for CD4+ 
T-helper cells in autoimmunity, antitumor immunity, and long-term immunity 
(102,103).  There is also accumulating evidence that the combined application of 
class I and class II epitopes derived from the same tumor antigen can potentiate 
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durable antitumor effector function (104-106).  We explored this potential with our 
TRP-1 model.  After elucidating the substantial difference in the TRP-1 T cell 
immune response mounted by WT and Bw cohorts, we proceeded to assess the 
antitumor efficacy of both respective CD4+ T cell populations, when adoptively 
transferred into melanoma challenged mice.   
 
Using genetically MHC-mismatched combinations of tumors and tumor-bearing 
hosts, we also showed that fully polarized high IFN-γ producing Th1 CD4
+ T cells 
eradicate established lung metastases in a manner that is both melanoma-
specific and DR4-restricted.  More importantly, we showed that this antitumor 
effect was more efficacious when mediated by CD4+ T cells-derived from 
antigen-deficient donors.  These results were, therefore, consistent with the 
aforementioned differences in T cell sensitivity.  Although cells from WT and Bw 
mice were infused into TRP-1 “self”-expressing DR4 Tg mice, systemic 
expression of TRP-1 seemed to have no apparent deleterious effect on the Bw 
cells‟ ability to outperform their WT counterparts in tumor destruction. 
 
By depleting individual individual lymphocyte populations with monoclonal 
antibodies, we then demonstrated that the antitumor effect is entirely dependent 
on host CD8+ T cells.  Although a Kb-restricted epitope from TRP-1 has been 
previously described (107), it is still unknown what specific antigen or restriction 
element is used by the cytotoxic T cells (CTLs).  We had found that MCA-205 
stably transfected with mTRP-1 was rejected after adoptive transfer but not a 
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control GFP transfectant (data not shown, C. Touloukian) confirming that 
antitumor responses were indeed TRP-1-specific.  The results, however, still do 
not exclude the contribution of other antigens to the overall effector CD8+ 
response.  Regardless of the CD8+ T cell clone or clones in question, it is clear 
that they require expression of HLA-DR4, presumably on host APCs.  The ability 
of activated, adoptively transferred CD4+ T cells to treat established tumor 
suggested that endogenous APCs are unable, on their own, to activate CD8+ T 
cells, but become de novo-induced after adoptive transfer.  It is also important to 
note that specific CD4+ T cells were incapable of recognizing the TRP-1277–297 
epitope when presented on murine class I or II (present on C57BL/6 
splenocytes), thus excluding a false positive interaction between the effector 
population and tumor. 
 
In the final immunotherapy experiment, we demonstrated, unexpectedly, that the 
tumor treatment effect was unimproved (with increased numbers of infused cells) 
after the depletion of host Tregs.  WT TRP-1-specific CD4 T cells were more 
effective against tumor when host Tregs were depleted, whereas the cells derived 
from the Bw mice were maximally active against tumor and thus capable of 
overcoming the inhibitory effects of Tregs.  In contrast, despite their high avidity 
and action against a highly immunogenic foreign antigen, OT-I CD8+ T cells were 
relatively less effective in Treg-replete hosts than the autoreactive Bw-derived T 
cell population.  So far, there is a dearth of evidence that the host tumor-bearing 
state or the relatively naïve unprimed state of the endogenous APC pool has any 
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negative effects on the ability of activated, high-avidity CD4+ T cells to provide 
help to antitumor CD8+ T cells.  
 
Although other investigators have used either ubiquitous or foreign antigen 
models or used TCR transgenic T cells, our immunotherapy data demonstrated 
that the adoptive transfer of nontransgenic CD4+ T cells specific for a normally 
expressed endogenous self/tumor antigen could directly cross-prime host-
derived endogenous CD8+ T cells.  Reports in the literature indicate that CD4+ T 
cells recognize antigen/MHC complexes either on classical APCs or on class II- 
expressing endothelial cells.  CD4+ T cells in turn activate or condition dendritic 
cells (DCs), principally through the interaction of CD40 with its ligand, resulting in 
the up-regulation of B7-1, B7-2, and OX40 costimulatory molecules (31,32,108).  
Conditioned DCs can then cross-present antigen to cognate CD8+ T cells at the 
tumor site or in remote locations (109).  We hypothesized that the antitumor 
effects of the transferred CD4+ T cells could occur by several different 
mechanisms of action, including: the release of cytokines that directly kill tumor 
or the supporting stroma; the activation of APCs that in turn activate NK/NKT 
cells or macrophages that in turn kill stromal cells; or through the activation of 
APCs which in turn cross-prime and activate CD8+ T cells on the same APC.  It is 
also plausible that IFN-γ production by CD4+ T cells potentiates or enables the 
action of CTLs either by up-regulating tumor MHC class I and/or by enhancing 
the antigen processing.  In the end, our pre-conditioning studies revealed that 
host CD8+ T cells were required for tumor elimination. 
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Despite substantial evidence that Tregs are crucial in maintaining self-tolerance 
and blunting the onset of autoimmunity and tumor immunity, the most surprising 
result was the demonstration that the suppressive actions of Tregs are not 
absolute.  In particular, we discovered that the actions of high-avidity 
autoreactive CD4+ T cells can overcome Tregs and mediate tumor immunity.  High 
avidity CD8+ T cells have been shown to be susceptible to regulatory 
suppression in similar adoptive transfer and tumor treatment models (110,111), 
including suppression generated within the immediate tumor microenvironment 
(112).  In our hands, high avidity OT-I CD8+ T cells were in fact susceptible to 
suppression.  Tregs are thought to oppose the sustained activation and expansion 
of CD4+ and CD8+ T cells through the secretion of suppressive cytokines (IL-10 
and TGF-β) the engagement of CTLA-4 or PD-1, the down-regulation of DC 
antigen presentation function, or through the direct elimination of autoreactive 
CD4+ T cells (113-116).  However, the adoptive transfer of high avidity CD4+ 
TRP-1-specific T cells may override these constraints of regulatory suppression.  
For example, an overwhelmingly strong avidity interaction between TCR and the 
antigen/MHC complex may counterbalance the actions of CTLA-4 or PD-1.  This 
would explain the observed potent suppression of WT (tolerized) TRP-1-specific 
CD4+ T cells as opposed to weak or nonexistent suppression of Bw (non-
tolerized) T cells.  A second explanation for this trend could be based on the 
release of cytokines (perhaps the high level release of IFN-γ alone by Bw T cells) 
which counterbalances the suppressor cytokines released by Tregs. 
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The TRP-1 vaccination and immunotherapy results highlight the importance of 
isolating high-avidity T-helper cells.  The antitumor potency of CD4+ T cells is still 
largely untested, and the exploitation of T cells derived from antigen-deficient 
hosts, as demonstrated in the tumor treatment studies, magnifies their potential 
experimental and clinical utility.  High avidity CD4+ T cells have the capacity to 
disrupt homeostatic balance and overcome the inhibitory effects of Tregs.  A 
further advantage of this model system is that it relies on a normally expressed 
self-antigen, presented by the most common class II allele (DR4) in patients with 
metastatic melanoma (117,118).  The binding of the hTRP1 peptide to HLA-DR1, 
DR7, and DR11 has also been found to be very high (data not shown), thus 
expanding the potential scope of its clinical application to more than 50% of 
patients with melanoma (119).   
 
Unlike other models, our system also did not involve the exogenous 
administration of IL-2 or vaccination or require myelodepletion to facilitate the 
antitumor effects.  These results further emphasize the self-sufficiency of high-
avidity T cells introduced into transplant recipients.  We believe these overall 
findings have tremendous therapeutic implications if TCR genes from CD4+ T 
cells can be isolated from antigen-deficient hosts and transferred either to 
peripheral T cells or hematopoietic stem cells.  Doing so will maximize the 
therapeutic efficacy that can be achieved with adoptive transfer of CD4+ T cells. 
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Chapter 2 
The results in Chapter 1 revealed the magnitude of immune tolerance to the self-
antigen, TRP-1.  Systemic expression of this antigen effectively blunts the 
sensitivity and cytokine potency of CD4+ T cells specific for its 277-297 epitope 
significantly inhibiting their ability to recognize and eliminate a challenge with 
antigen-positive melanoma cells.  Given the significance of these findings, we 
decided to query a specific mechanism of tolerance that could be responsible.  
Globally, immune suppressive mechanisms include deletion, anergy, regulation, 
activated-induced cell death and ignorance.  Each of these blunts autoimmune 
responses to self-antigens. From a developmental standpoint, promiscuous 
expression of tissue-specific genes within medullary thymic epithelial cells 
(mTECs) has emerged as a powerful mechanism of central tolerance.  Deletion 
of immature thymocytes serves as an initial gatekeeping stage to prune the entire 
T cell repertoire before it can even reach the systemic circulation.  Although RNA 
transcripts of the MDAs gp100 and tyrosinase have been detected in mTEC RNA 
by polymerase chain reaction, no causal relationship to thymic selection has 
been demonstrated.  To date, no studies in the literature have confirmed that 
TRP-1 is expressed within mTECs.  However, it has been shown that TRP-1 is 
the most abundant glycoprotein in melanocytic cells, and a secreted fraction of 
the protein has been found to contain the 277 to 297 epitope (120).  Given these 
circumstantial findings, we hypothesized that negative selection of the TRP-1 
specific T cell repertoire could be mediated by ectopically presented antigen from 
mTECs or thymic DCs. 
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The broad framework for our interest in central tolerance was the modest results 
of past clinical studies that employed immunotherapy modalities for melanoma.  
Vaccine trials have attempted to deliver highly potent stimuli for T cells specific 
for tumor antigens.  Additionally, adoptive transfer studies have aimed to 
introduce into patients T cells transduced with a functional TCR, often derived 
from a T cell clone previously cultivated from TIL.  Attempting to engage the host 
T cell response by immunizing or utilizing gene therapy with TCRs poses a 
paradoxical challenge if, in fact, our hypothesis that central tolerance eliminates 
the most potent tumor reactive thymocytes is valid.  Thymic deletion of tumor 
reactive T cells, such as those specific for TRP-1, preempts targeting of said 
cells by these modalities.  Even when priming with the most optimal vaccine 
regimen or cloning the most highly-avid TCR for gene therapy, these methods 
are ultimately drawing from a population of TCRs that has been pruned by thymic 
selection.  Therefore, they manifestly fail to achieve the true immune potency that 
would be directed at a foreign antigen. 
 
Our first objective was to clarify the expression status of the TRP-1 antigen in the 
Bw mouse population.  This information would help classify its status as a foreign 
or self protein with respect to the immune system.  Data on the Bw mouse in the 
literature was suggestive of TRP-1 deficiency: the cappuccino coat color 
phenotype (as opposed to the normally pigmented black), the defined gene 
inversion of exon 1 within the Tyrp1 locus as well as RT-PCR studies of whole 
skin homogenates (121).  We grossly compared Bw to WT mice by first acquiring 
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skin samples for histology and staining.  Sections from both populations were 
stained with S100 Ab, specific for cells of neural crest origin, and thus a marker 
for melanocytes in the epidermis.  Interestingly, while Bw cells did have some 
melanocytes in proximity to the hair follicle, they were extremely sparse in 
comparison to the WT skin section.  TRP-1 is an important cofactor in melanin 
biosynthesis, but it has also been linked to a feedback mechanism with the 
upstream transcription factor Mitf, an important master controller of melanocyte 
survival and proliferation (122).  The histology results suggest that the Bw 
genotype reduces antigen levels on a molecular level with reduced gene 
expression as well as a macro level with attrition of the melanocyte population.  A 
difference in peripheral antigen levels between WT and Bw mice is significant for 
central tolerance, particularly in the context of class II antigen presentation.  
Investigators have shown that dendritic cells from the periphery are capable of 
acquiring exogenous antigen, migrating to the medullary region of the thymus, 
and mediating deletion of corresponding antigen specific T cells (70).  A marked 
reduction in class II epitope levels in the periphery would correspond to a 
decrease in trafficking of the epitope to the thymus for presentation and 
tolerization of cognate TCR-bearing thymocytes. 
 
Besides dendritic cells carrying peripheral epitopes to the thymus, many studies 
(described in the introduction) have implicated the medullary thymic epithelium 
as the central mediator in promiscuous gene expression of self antigens and 
elimination of corresponding thymocytes with self-reactive TCRs.  For example, 
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several models of mTEC mediated tolerance have centered around the APECED 
syndrome (autoimmune polyendocrinopathy) associated with infiltrates of 
autoimmune T cells in endocrine tissues.  The causality for this disease has been 
linked to a defect in the prominent mTEC transcription factor, Aire.  Normally, 
Aire promotes promiscuous gene expression of endocrine family genes such as 
insulin, mucin-6 and thyroglobulin.  Loss of Aire and its associated downstream 
targets is attributed to the autoimmune syndrome.  We investigated whether an 
analogous Aire:TRP-1 transcription axis exists in thymic epithelium.  To do so, 
we isolated mTECs from WT mice to analyze RNA samples to probe for TRP-1 
gene expression.  Interestingly, we found that TRP-1 mRNA was detectable in 
WT mTECs.  Furthermore, we utilized immunofluorescent staining with an anti-
TRP-1 Ab and were able to image detectable levels of TRP-1 protein in a subset 
of mTEC cells.  This finding is consistent with reported patterns of promiscuous 
gene expression in the literature which suggests that, often, only a fraction of 
mTECs ectopically express a given host antigen (123).  Importantly, our 
discovery that TRP-1 is expressed in mTECs implies a role for central tolerance 
as modulator of the TRP-1-specific T cell repertoire.   
 
Having found that TRP-1 is expressed by mTECs, our next focus was to test 
whether activation of the tyrp1 gene could be attributed to a particular 
transcription factor.  Aire is conventionally denoted as the master promoter of 
promiscuous gene activation in mTECs, as it has been shown to promote 
expression of various tissue associated antigens.  At the same time, Mathis and 
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colleagues have conducted genome-wide array analyses of RNA samples from 
Aire-/- mTECs which showed that some genes are promiscuously expressed 
independently of Aire and others appear to be elevated in the absence of Aire 
(124).  To expand the experiment beyond Aire, we also considered the Mitf 
protein which is the central controller of TRP-1 expression in peripheral 
melanocytes.  With Aire and Mitf as targets of consideration, we isolated mTEC 
RNA from Aire-/- and Mitf-/- mice to compare with WT and Bw mTEC RNA in qRT-
PCR gene expression assays.   
 
First, we tested for expression of TRP-1 and found that RNA copy number in the 
Mitf-/- sample was indistinguishable from the WT. This result was not unexpected 
since there is little evidence in the literature of mTECs utilizing conserved 
transcriptional programs from peripheral tissues for promiscuous expression 
antigens.  The second notable result was that TRP-1 levels in the Aire-/- sample 
were actually elevated compared to the WT by approximately 7-fold.  This could 
imply that TRP-1 expression is suppressed by the Aire protein, whether through 
direct regulation or an indirect pathway.   
 
The next question posed by these findings is what transcription factors or gene 
modification processes are responsible for upregulating expression of TRP-1 in 
mTECs.  With no apparent role of the conventional transcriptional program seen 
in melanocytes or of the transcription factor Aire, one possible explanation is 
chromatin modifications.  Investigators have recently turned their attention to the 
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role of histone acetylation/deacetylation of mTEC DNA in permitting promiscuous 
expression to occur (125).  By loosening gene promoter sites, which permits 
RNA polymerase cofactors to bind and initiate a transcription complex, histone 
modifications in mTECs could efficiently enable the promiscuous expression of 
tissue antigens including TRP-1.  This is an area of mTEC biology that is only 
beginning to be revealed. 
 
Besides probing the Tyrp1 gene, we performed additional qRT-PCR assays with 
the mTEC samples to assess expression of the transcription factors Aire and 
Mitf.  The first notable finding was that the Aire-/- sample exhibited a 2 log 
increase in Mitf expression compared to the WT.  It is not clear whether there is a 
unified mechanism responsible for the concomitant increase in TRP-1 and Mitf in 
this population (such as de-repression of both genes in the absence of Aire).  An 
alternative possibility is that Mitf is independently de-repressed in the Aire-/-, and 
its increased expression leads to upregulation of the Tyrp1 gene.  Results from 
the Mitf-/- mTEC sample were also unexpected.  There was a log-fold decrease in 
Aire expression compared to the WT sample, and an assay for expression of 
Insulin showed a log-fold decrease in transcript levels relative to the WT.  These 
results are interesting when considered in the context of the flow cytometry data 
for the respective mTEC population sorts.  The flow sort of the WT population 
returned 10-20% of the input cells matching the mTEC staining profile, whereas 
the Mitf-/- sort returned only 2% of input cells.  Though we hypothesized that Mitf 
would promote TRP-1 expression in mTECs, these results may imply a role for 
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Mitf in regulating Aire expression and possibly mTEC maturation at the cellular 
level.   
 
After investigating the transcriptional profile of TRP-1 and its potential regulators 
in mTECs, we next sought to analyze the developmental fate of TRP-1 specific T 
cells in the thymus.  We utilized donor mice expressing a transgenic I-Ab 
restricted TRP-1-specific TCR.  Whole bone marrow was transplanted into 
lethally irradiated WT, Bw and DR4 Tg (I-Ab-/-) recipients which were 
subsequently analyzed after reconstitution.  It was hypothesized that WT mice, 
with TRP-1 expressing mTECs, would preferentially delete developing TRP-1-
specific thymocytes resulting in fewer cells with the transgenic TCR surviving to 
the CD4+ SP stage.  We performed flow cytometry on thymocytes from the 
transplanted mice and found, contrary to our hypothesis, that the percentage of 
Vβ14+ CD4+ SP cells (TCR transgene positive) was statistically indistinguishable 
between all three groups with a range of 42-44%.  Furthermore, Annexin V 
staining was performed to characterize the degree of apoptosis in Vβ14+ CD4+ 
SP cells, and the differences between the populations were statistically 
insignificant (in the range of 6-7%).  Splenocytes were also harvested and 
analyzed to determine the prevalence of Vβ14+ CD4+ T cells in the periphery.  
The WT population showed a slightly lower prevalence of transgenic T cells 
compared to Bw and DR4Tg (44% compared to 50% and 51%, respectively), but 
the differences were not statistically significant.   
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Overall, the transplant findings did not reveal the expected difference in central 
tolerance to TRP-1 between the WT and Bw populations that we hypothesized 
based on the vaccination studies.   One explanation for this finding could be a 
transplant effect – hematopoietic depletion by irradiation leads to a systemic 
equilibrium shift in the host that induces IL-7 release to facilitate substantial 
repopulation of blood cells (126).  This shift may be more permissive for cell 
development in the thymus and, to some extent, override thymic selection.  A 
second possibility is that the avidity of the transgenic I-Ab TCR used in the 
transplant experiment was below the threshold for negative selection.  As shown 
in the WT and Bw vaccination studies, TRP-1-specific T cells do expand in a 
vaccinated WT population, but they are of markedly diminished potency which is 
likely indicative of lower avidity cells surviving negative selection in the thymus.  
Repeating these studies with competitor non-transgenic bone marrow would 
possibly allow for contrasting survival of the TRP-1-specific thymocytes with a 
general thymocyte population.  Finally, communicated data from the Restifo lab 
strongly suggests that the Vβ14 chain of the transgenic can mispair with de novo 
alpha chains produced by the T cell, thus creating a different composite TCR 
than the TRP-1 moiety.  The T cells bearing such TCRs, if not specific for TRP-1 
or another self antigen, would escape negative selection.  Our flow cytometry 
analysis staining for anti-V β14 would not have distinguished between the 
transgenic and mispaired TCR bearing T cells.  
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Our final analysis was a pilot study to assess promiscuous gene expression in 
DCs.  Bevan and colleagues have already shown that DCs may be the primary 
mediators of negative selection of thymocytes with class II restricted TCRs (67).  
This includes a subpopulation that differentiates from resident lymphoid 
progenitors in the thymic medulla, cells which are thought to acquire and present 
exogenous antigens provided locally by promiscuously expressing mTECs (69).  
Additionally, DCs inhabiting various peripheral tissues migrate to the thymic 
medulla carrying antigen from the periphery; they present peripheral epitopes to 
developing thymocytes thereby mediating deletion of self-reactive cells.  Given 
the growing interest in the contribution of DCs to central tolerance, we peformed 
a qRT-PCR assay to assess whether they can express the Tyrp1 gene 
themselves.  In a pilot experiment with RNA from WT mTECs and DCs (CD11c+ 
MHC class II+) sorted from thymic, splenic and lymph node tissue, we compared 
relative transcript levels of TRP-1 among the samples.  Interestingly, our 
preliminary results show that TRP-1 transcript is expressed in all of the DC 
populations.  Notably, the differences between each of the samples are within a 
4-fold range.  Based on these intriguing findings, we will expand our investigation 
of central tolerance to consider the impact of DCs on the TRP-1 T cell repertoire.  
Additionally, we will continue to investigate the hypothesis of a DC contribution to 
central tolerance that includes not only antigen acquisition and presentation, but 
also promiscuous antigen expression (Figure 33). 
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Figure 33. Theoretical model for promiscuous antigen expression in central 
tolerance.  mTECs have already been shown to express an array of self 
antigens, and DCs are known to contribute to deletion of CD4+ SP cells.  A 
potential new role for DC expression of self-antigens is suggested by the data 
and will be analyzed in future studies. 
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FUTURE OBJECTIVES 
Chapter 1 experiments showed the potency of TRP-1 specific T cells derived 
from Bw mice.  They displayed a characteristic Th1 phenotype with secretion of 
IFN- γ cytokine, even at diminishing peptide antigen concentrations.  Adoptive 
transfer experiments with tumor challenged mice illustrated the melanoma 
treatment efficacy of these CD4+ T cells.  The experiments controlled for antigen 
specificity in the tumor response and showed that CD8+ cells in the recipient 
hosts were necessary for the tumor treatment effect.  These experiments did not 
prove IFN- γ was the operative cytokine directly stimulating the anti-melanoma 
immune response.  To better answer this question, we will employ IFN- γ-/-// Bw 
mice for vaccination and derivation of an IFN- γ deficient population of TRP-1 
specific T cells.  Utilizing these cells for repeat adoptive transfer experiments in 
mice challenged with B16 melanoma will reveal whether, and to what extent, this 
cytokine is responsible for the tumor treatment efficacy observed in the original 
experiment.   
 
Our second future aim is to clarify the impact of Tregs on the tumor treatment 
efficacy of TRP-1 specific T cells.  Adoptive transfer of cells derived from the WT 
cohort was consistent with the literature in that depletion of Tregs in the tumor 
challenged hosts with PC61 Ab resulted in a significantly enhanced tumor 
treatment efficacy.  However, the cohorts receiving Bw cells had the same 
treatment outcomes, irrespective of depletion with PC61 Ab or administration of 
control IgG.  Data in the literature suggests a role for host Tregs in suppressing the 
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tumor response.  For example, they have been shown to migrate to tumors in 
large numbers by following a CCL22 gradient (127).  Within the tumor or tumor 
draining lymph node, they become activated and expand, and more than one 
clinical study has shown that elevated Tregs in tumor tissue correlates with a 
poorer prognosis (128,129).  Our immunotherapy studies showed that even the 
most optimally treated mice still had an average of 5 pulmonary tumor nodules at 
the end of the experiment, leaving room for improving the efficacy.  A suppressor 
effect from residual Tregs or even phenotypic conversion of a subset of the 
adoptively transferred cells to Foxp3+ are two possible avenues for Treg 
suppression following adoptive transfer of high-avdity Teffectors.  We plan to test 
this question with an absolute reduction of Treg numbers by utilizing Foxp3
-/- 
tumor challenged hosts.  The tumor treatment studies with Bw donor cells will be 
repeated with two cohorts: WT and Foxp3 knockout mice versus WT mice.  This 
experiment will assess if the high potency T cells achieve superior efficacy in the 
complete absence of Treg cells. 
 
Future experiments will also identify which mechanisms of tolerance suppress 
the immune response to TRP-1.  Vaccination studies described in Chapter 1 
illustrated the significance of the host‟s tissue expression profile in determining 
the immune potency of responding T cells.  Additionally, analyses of thymic 
tissue in Chapter 2 revealed that the TRP-1 antigen is expressed in mTECs of 
WT mice.  These findings implicate a contribution of negative selection to the 
immune tolerance manifested towards this antigen.  To unify these concepts, we 
99 
 
will perform vaccination studies on WT and Bw mice that have been 
thymectomized and transplanted with a Bw or WT thymus, respectively.  With 
four groups (listed as host-donor thymus): WT-WT, Bw-Bw, WT-Bw, Bw-WT, we 
will be able to isolate the impact of negative selection by thymic deletion from all 
other tolerance mechanisms mediated by the host.  By comparing the cytokine 
release profiles from the four groups, we will be able to quantify the direct effect 
of central tolerance on the TRP-1 specific T cell repertoire. 
 
Besides isolating the impact of central tolerance, the aforementioned experiment 
will reveal if, and to what extent, other tolerance mechanisms of the host are 
affecting the TRP-1 T cell response.  For example, a result where mice in the 
WT-Bw cohort produce lower potency T cells than the TRP-1 Bw-Bw cohort 
would illustrate that other processes besides thymic deletion, such as peripheral 
tolerance in the lymph nodes, should be examined.  More recent studies have 
examined a newly defined population of epithelial cells that appear to play a role 
in mediating deletion of T cells expressing TCRs specific for host antigens 
(130,131).   We plan to analyze these eTACS (extrathymic Aire-expressing cells) 
for gene expression, in a similar manner as our mTEC studies to determine if 
they are comparable to mTECs in their levels of TRP-1, Aire and Mitf.  These 
studies will further expand our scope of understanding about where and how the 
host tolerizes its T cell repertoire with the goal of better understanding the 
mechanisms limiting tumor immunotherapy. 
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